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ABSTRACT 
 
3,4-Methylenedioxymethamphetamine (MDMA or ―ecstasy‖) is a well-known 
psychoactive drug, with acknowledged neurotoxic properties. It is commonly used in 
recreational settings by many teenagers and young adults. Despite the great deal of study 
on MDMA neurotoxicity, the consequences of MDMA exposure during the adolescent 
period require additional research. Moreover, MDMA effects on the cerebellum and 
peripheral organs have been scarcely studied. The susceptibility of different aged groups 
is also poorly known.  
This dissertation aimed to assess the acute toxicity of a MDMA binge dose regimen 
comparable to human usage in four different brain areas (cerebellum, hippocampus, 
cortex and striatum), and in three peripheral organs (liver, heart and kidneys) in an 
adolescent rat, 24 h after MDMA binge administration. Another aim was to evaluate the 
long-term neurotoxicity of the binge MDMA dose regimen in the cerebellum, by assessing 
its energetic and oxidative stress status in adolescent and old rats, seven days after 
MDMA administration. 
To achieve the aims of the present dissertation, two experiments were conducted. In 
experiment one, adolescent male Wistar rats (postnatal day 40) were divided in two 
groups and treated: control saline (three doses of NaCl 0.9%, intraperitoneally, every 2 h, 
n=7) and MDMA-treated (three doses of MDMA 5 mg/Kg, intraperitoneally, every 2 h, 
n=7). The temperature of each animal was monitored for 7 h after the first injection. 
Twenty-four hours after the MDMA administration, brain areas were dissected and the 
peripheral organs were collected. A significant hyperthermia in the adolescent rats was 
observed after MDMA exposure. No differences were found between controls and MDMA-
treated groups in body weight gain, as well as in food or water consumption, within the 
experimental period. Adenosine triphosphate (ATP) content was significantly decreased in 
the cortex of MDMA-treated rats, but not in the other areas. In all brain areas, no 
alterations were found in glutathione, quinoproteins and protein carbonylation levels in 
MDMA-treated animals. In liver, heart and kidneys no differences were found in 
glutathione, protein carbonylation or ATP levels, after MDMA exposure. However, the 
formation of protein-bound quinones was significantly increased in the liver of MDMA-
treated rats, but not in the other two peripheral organs. The histological hepatic 
examination of adolescent MDMA-treated rats revealed a marked cellular vacuolization in 
the periportal regions, and sinusoidal dilatation with periportal and centrilobular vascular 
congestion. In the heart, MDMA promoted punctual signs of cardomyocyte oedema, 
particularly in the sub-endocardic region. In the kidneys of MDMA-treated adolescent rats, 
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scattered interstitial oedema, with dilatation between the nefrotic tubular structures, and 
signs of vascular congestion were found. The lack of severe cellular damage and/or 
necrosis in MDMA-treated rats is corroborated by the lack of increase of caspase-3, -8 
and -9 activities or changes in the plasma biomarkers of liver or heart injury. 
Experiment two was conducted with adolescent (postnatal day 40) and aged (18 to 
22 months old) male Wistar rats. Animals were divided in two groups: control saline (n=5) 
and MDMA group (n=5) that were treated as described for experiment one. Seven days 
later, animals were sacrificed and the cerebellum was collected. Aged animals did not 
receive the third dose of MDMA given the high risk of mortality, due to the hyperthermic 
response verified after the second MDMA administration. Until sacrifice, animal weight 
and food/water consumption were registered daily. Despite the exposure to a lower 
cumulative dose the hyperthermic response was more pronounced in aged rats than in 
adolescents, and the temperature of aged rats remained significantly elevated 24 h after 
drug exposure. MDMA promoted decreases in adolescent animals‘ body weight at 24 h 
post-MDMA administration. In aged animals, the food intake suffered a biphasic response 
after MDMA exposure: at 24 h a decrease was observed, while at 48 h an increase in 
consumption occurred in MDMA-treated animals, when compared to aged controls. The 
water intake was significantly increased in aged animals, 24 and 48 h after MDMA 
exposure. In the cerebellum, all the oxidative stress parameters remained unaltered in 
both adolescent and aged MDMA-treated rats, whereas decreases in the ATP content 
were seen in MDMA-treated aged rats.  
Altogether, these results suggest that moderate MDMA doses do not promote any 
significant alterations in the oxidative stress parameters in the adolescents‘ brain areas, 
24 h after the exposure. Importantly, the MDMA binge scheme used in adolescent animals 
promoted morphological tissue alterations to the peripheral organs. Regarding the age 
factor, a long-term ATP decrease was seen in the cerebellum of aged rats, indicating a 
higher susceptibility of this group to MDMA. Further investigation is needed to evaluate 
the impact of moderate MDMA doses either in the brain as in peripheral organs of 
adolescent animals, and to explore the dissimilar effects of MDMA to different aged 
animals.  
 
 
Keywords: Amphetamines, "Ecstasy", Adolescence, Rats, Brain, Peripheral organs, 
Oxidative stress, Toxicity. 
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RESUMO 
 
A 3,4-metilenodioximetanfetamina (MDMA ou ―ecstasy‖) é uma substância psicoativa 
bastante conhecida, com propriedades neurotóxicas bem documentadas. É 
habitualmente consumida em contextos recreativos, principalmente entre os adolescentes 
e jovens adultos. Apesar de existirem imensos estudos acerca da neurotoxicidade da 
MDMA, as consequências da exposição a esta substância durante a adolescência 
requerem, ainda, mais investigação. Para além disso, os efeitos da MDMA no cerebelo e 
nos órgãos periféricos têm sido alvo de poucos estudos. Acrescente-se que pouco se 
sabe sobre a suscetibilidade de diferentes faixas etárias a esta droga de abuso. 
Esta dissertação teve como objetivo avaliar a toxicidade aguda decorrente de um 
regime de MDMA, comparável ao utilizado pelos humanos, em quatro áreas do cérebro 
(cerebelo, hipocampo, córtex e corpo estriado), e três órgãos periféricos (fígado, coração 
e rins) em ratos adolescentes, 24 h após a administração de MDMA. Outro objetivo 
centrou-se na avaliação da toxicidade a longo prazo a nível do cerebelo, decorrente da 
administração repetida de MDMA. Para atingir os objectivos propostos foram avaliados 
quer parâmetros de stress oxidativo, quer do estado energético, em ratos adolescentes e 
idosos, sete dias após a administração de MDMA. 
De forma a atingir os objetivos traçados nesta dissertação, foram levados a cabo 
dois trabalhos experimentais distintos. No primeiro, ratos Wistar macho (40 dias de idade) 
foram divididos em dois grupos e tratados: controlo salino (três doses de NaCl 0.9 %, 
intraperitonealmente, a cada 2 h, n=7) e tratados com MDMA (três doses de MDMA 5 
mg/kg, intraperitonealmente, a cada 2 h, n=7). A temperatura de cada animal foi 
monitorizada durante 7 h após a primeira injeção. As áreas cerebrais foram dissecadas e 
os órgãos periféricos recolhidos 24 h após a administração de MDMA. Após a exposição 
à MDMA foi observada hipertermia nos ratos adolescentes. Não foram encontradas 
diferenças entre o grupo controlo e o grupo tratado com MDMA no que diz respeito ao 
ganho de peso, consumo de água e ingestão de alimentos, durante o período 
experimental. O conteúdo de adenosina trifosfato (ATP) diminuiu significativamente no 
córtex dos ratos tratados com MDMA, mas não em outras áreas cerebrais. Nos animais 
tratados com MDMA não foram observadas alterações nos níveis de glutationa, 
quinoproteínas e carbonilação proteica, em todas as áreas cerebrais estudadas. No 
fígado, coração e rins dos animais não se encontraram alterações nos níveis de 
glutationa, carbonilação proteica e ATP, após a exposição à MDMA. No entanto, houve 
um aumento significativo da formação de quinoproteínas no fígado dos ratos tratados 
com MDMA, mas não nos restantes órgãos estudados. A observação histológica do 
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fígado dos ratos adolescentes tratados com MDMA, revelou vacuolização celular nas 
regiões periportais e um alargamento dos espaços sinusoidais com congestão sanguínea 
periportal e centrilobular. No coração dos animais tratados com MDMA, foram 
observados pontualmente cardiomiócitos edemaciados, particularmente na região sub-
endocárdica. Nos rins de ratos adolescentes tratados com MDMA foram encontrados 
sinais de edema intersticial disperso com alargamento do espaço entre as estruturas 
tubulares dos nefrónios, assim como sinais de congestão sanguínea. A ausência de dano 
celular acentuado e/ou necrose em ratos adolescentes tratados com MDMA é 
corroborada pelo facto de não se ter verificado aumento nas atividades das caspases 3, 8 
e 9, ou alteração nos níveis plasmáticos dos biomarcadores de lesão cardíaca ou 
hepática. 
O segundo trabalho experimental foi executado com ratos Wistar macho 
adolescentes (40 dias de idade) e ratos idosos (18 a 22 meses de idade). Os animais 
foram, mais uma vez, divididos em dois grupos: controlo salino (n=5) e grupo tratado com 
MDMA (n=5), administrados como descrito no primeiro trabalho experimental. Sete dias 
depois, os animais foram sacrificados e o cerebelo foi recolhido. Os animais idosos não 
receberam a terceira dose de MDMA, dado o elevado risco de mortalidade decorrente da 
resposta hipertérmica verificada após administração da segunda dose da droga. Até ao 
sacrifício dos animais, o seu peso, ingestão de água e alimentos foram registados 
diariamente. Apesar dos ratos idosos terem sido expostos a uma dose total de MDMA 
menor que a dos ratos adolescentes, a resposta hipertérmica dos ratos idosos foi mais 
pronunciada e a temperatura dos mesmos manteve-se significativamente elevada 24 h 
após a exposição à droga. A MDMA levou à perda de peso nos ratos adolescentes, 24 h 
após a sua administração. Relativamente aos animais idosos, na ingestão de alimentos 
verificou-se uma resposta bifásica após a exposição à MDMA: foi observada uma 
diminuição às 24 h, enquanto que às 48 h houve um aumento no grupo de animais 
tratados com a droga em comparação com os animais controlo. A ingestão de água 
aumentou significativamente nos animais idosos, 24 e 48 h após a exposição à MDMA. 
Ao nível do cerebelo, todos os parâmetros de stress oxidativo se mantiveram inalterados 
nos animais adolescentes e idosos tratados com MDMA, enquanto que houve uma 
diminuição do conteúdo de ATP nos animais idosos expostos à droga. 
Analisando todos os resultados, estes parecem sugerir que doses moderadas de 
MDMA não levam a alterações notórias nos parâmetros de stress oxidativo nas áreas 
cerebrais dos ratos adolescentes, 24 h após a exposição à droga. É importante referir 
que o regime de administração de MDMA usado nos animais adolescentes levou ao 
aparecimento de alterações morfológicas nos tecidos dos órgãos periféricos. Tendo em 
conta o fator idade, foi observada uma diminuição dos níveis de ATP, a longo prazo, no 
xvii 
cerebelo de ratos idosos, indicando uma maior suscetibilidade deste grupo à MDMA. 
Será necessária uma investigação mais aprofundada para avaliar o impacto da exposição 
a doses moderadas de MDMA, quer no cérebro, quer nos órgãos periféricos, de animais 
adolescentes e explorar os efeitos da MDMA em animais de diferentes faixas etárias. 
 
 
Palavras-chave: Anfetaminas, "Ecstasy", Adolescência, Ratos, Cérebro, Órgãos 
Periféricos, Stress Oxidativo, Toxicidade. 
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1. INTRODUCTION 
 
1.1. An historical overview of amphetamines  
 
Amphetamines are psychoactive substances and members of the phenylethylamine 
family, which include a broad range of substances that may be stimulant, euphoric, 
anorectic, entactogenic or hallucinogenic agents (Carvalho et al 2012). Amphetamine 
(AMPH) has a phenyl ring, a two carbon side chain between the phenyl ring and nitrogen, 
an α-methyl group, and a primary amino group (Figure 1). This basic structural feature is 
shared by other amphetamine-type psychostimulants (ATS) that enable their typical 
pharmacological actions (Sulzer et al 2005). AMPH, methamphetamine (METH), and 3,4-
methylenedioxymethamphetamine (MDMA, ―ecstasy‖) are widely abused amphetamine-
like synthetic drugs, with the basic chemical structure of phenylethylamine. AMPH, METH, 
and MDMA may be ingested, snorted, and less frequently, injected, and they can be taken 
in form of tablet, powder, or capsule, and in METH‘s case the crystalline form can also be 
smoked (EMCDDA 2011).  
Their history starts at 1887 in Germany, where AMPH was synthesized for the first 
time (Greene et al 2008). For thousands of years, humans have used natural 
amphetamines-like compounds through the consumption of plants, namely Catha edulis 
(Khat) and various plants of the genus Ephedra (family Ephedraceae), including Ephedra 
sinica (má huáng). Chewing Khat‘s fresh leaves is a widespread habit in the local 
populations of East Africa and Arabian Peninsula, and the users report increased levels of 
energy, alertness, self-esteem, a sensation of elation, enhanced imaginative ability, and a 
higher capacity to associate ideas. Plant-derived stimulant Ephedra (má huáng), is one of 
the oldest known medicinal herbs, and has been used in Traditional Chinese Medicine for 
over 5000 years to treat asthma and the common cold (Kalix 1996). 
Over the past decades, MDMA, also known as ―ecstasy‖, ―XTC,‖ ―E,‖ and ―Adam,‖ 
has become widely used as a recreational drug by young people around the world. It was 
first synthesized in 1912 by Merck, and patented in 1914, but it was never produced 
commercially, nor did it achieve clinical use (Burgess et al 2000). MDMA has often been 
said to have been originally patented for use as an appetite suppressant, but it was 
actually first patented as a precursor agent for therapeutically active compounds, and was 
never intended for use as an anorectic drug (Freudenmann et al 2006).  
The toxicology of MDMA was examined in the year 1953 for the first time, together 
with other similar compounds, in a classified research program sponsored by the USA 
military, presumably as part of a chemical warfare program. In 1976, researchers 
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suggested that it might be useful as an adjuvant for psychiatric treatment (Green et al 
2003). Recreational use of ―ecstasy‖ began in United States in the late 1960s, and 20 
years later in Europe (Montoya et al 2002). 
The typical recreational use of AMPH, MDMA or METH is often characterized by a 
repeated pattern of frequent administrations of the drug during a short time period, also 
known as a binge administration (Badon et al 2002). 
 
Figure 1 – Chemical structures of β-phenylethylamine (numbered), amphetamine (AMPH), 3,4-
methylenedioxymethamphetamine (MDMA or ―Ecstasy‖) and methamphetamine (Meth, ―Ice‖). 
 
 
1.2. Epidemiology 
 
According to the World Drug Report 2014 of the United Nations Office of Drugs and 
Crime (UNODC), amphetamines (AMPH and METH) or ―ecstasy‖ are the second most 
commonly used illicit substances. The illicit drug abuse is commonly related with nightlife, 
which is more frequently attended by young people, but can also be associated with some 
specific social contexts and cultural groups (EMCDDA 2014, UNODC 2014). Among ATS, 
AMPH and MDMA are the most available in Europe (EMCDDA 2014, UNODC 2014).  
The 2013 annual report of the General-Directorate for Intervention on Addictive 
Behaviours and Dependencies (SICAD) states that the use of amphetamines by the 
Portuguese population became wider after 2007, being more frequent among the young 
population. Besides, ―ecstasy‖ is the third illegal drug most commonly used in Portugal, 
after cannabis and cocaine (SICAD 2013). 
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1.3. Pharmacology 
 
ATS are psychostimulants known to interact with monoamine transporter sites in the 
central nervous system (CNS). Amphetamines act as substrates for the membrane 
transporters of noradrenaline (NET), dopamine (DAT), and serotonin (5-HTT), due to the 
structural similarity with monoamine neurotransmitters, noradrenaline (NA), dopamine 
(DA) and serotonin (5-hydroxytryptamine; 5-HT) (Berger et al 1992, Crespi et al 1997, 
Jones et al 1998, Kegeles et al 1999, Rothman et al 2000, Silvia et al 1996). Thereby, 
they reduce the uptake of endogenous neurotransmitters to the cytoplasm and favour the 
reverse transport of endogenous neurotransmitters into the synaptic cleft, resulting in non-
exocytotic neurotransmitter release (Berger et al 1992, Crespi et al 1997, Sulzer et al 
1995). Amphetamines can also elevate cytoplasmic transmitter concentrations by 
promoting DA and 5-HT release from storage vesicles via vesicular monoamine 
transporter (VMAT), while preventing the uptake into vesicles, making neurotransmitters 
more readily available for reverse transport (Jones et al 1998, Partilla et al 2006, Rothman 
& Baumann 2003, Sulzer et al 1995). 
Although AMPH and its analogues present similar actions at several transporters, its 
principal mechanism of action is on DAT by increasing release of DA from the presynaptic 
nerve terminals (Jones et al 1998, Kegeles et al 1999, Silvia et al 1996). Thus, AMPH 
enters the cell by acting on DA terminals. This entry can occur via DAT, which is the most 
common route, or, it also can happen by AMPH lipophilic diffusion through the plasma 
membrane, which is only efficient at higher AMPH concentrations. The presence of the α-
methyl group leads to an increased ability to cross membranes due to its amphipathic 
nature. Moreover, AMPH structure prevents monoamine oxidase (MAO) enzyme ability to 
oxidize its amine group by the presence of the α-methyl group in its chemical structure 
(Figure 1) (Carvalho et al 2012, Jones et al 1998). In general, DA is mostly increased by 
AMPH in the synaptic cleft, by the mechanisms of reverse transport of VMAT and DAT, as 
referred above (Jones et al 1998, Partilla et al 2006, Sulzer et al 1995). 
In normal conditions, DA is metabolized to dihydroxiphenylacetic acid (DOPAC) by 
MAO (Davidson et al 2001). AMPH also influences DA-metabolic pathways, decreasing 
the levels of DOPAC, as a result of AMPH-induced MAO inhibition, thus prolonging the 
monoaminergic transmission (Jones et al 1998, Miller et al 1980, Taylor et al 2013). 
Likewise, METH is also an indirect monoaminergic agonist. It is a substrate of NET, 
DAT and 5-HTT and increases the levels of NA, 5-HT and DA in the synaptic cleft, by 
acting on their reuptake and also on storage vesicles (Brown et al 2000, Cruickshank & 
Dyer 2009, Rothman et al 2000). METH also prolongs monoaminergic transmission by 
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inhibiting MAO activity, which results in an additional increase of cytosolic DA (Larsen et 
al 2002).  
Table 1 summarizes some of the major findings regarding the pharmacodynamics of 
AMPH, MDMA, and METH. 
 
Table 1 – Relevant findings related with amphetamines pharmacological mechanism of action. 
Findings References 
In vivo studies in rats demonstrate that AMPH acts as a DA releaser. 
(Chiueh & Moore 
1975, Sulzer & 
Rayport 1990, Von 
Voigtlander & 
Moore 1973) 
Studies in the mouse brain indicated that MDMA causes an efflux of 5-
HT, DA, and NA. 
(Johnson et al 
1986, Nichols et al 
1982) 
It was shown that MDMA interacts with monoamine carriers, leading to a 
non-exocytic release of 5-HT, DA and NA, in the mouse brain. 
(Berger et al 1992, 
Crespi et al 1997) 
In vivo microdialysis showed that MDMA induces DA and 5-HT release in 
the rat brain, and the effects of the drug on 5-HT release were 
predominant. 
(Baumann et al 
2005, Yamamoto & 
Spanos 1988) 
Experiments in vitro using Planorbis corneus giant dopamine cells 
indicated that AMPH decreases vesicular DA content, and redistributes 
the neurotransmitter to the cytosol, promoting reverse transport, and DA 
release. 
(Sulzer et al 1995) 
Experiments in human embryonic kidney 293 cells indicated that AMPH 
is a substrate of the human DAT. 
(Sitte et al 1998) 
Studies with DAT knockout (DAT - / -) mice, after AMPH administration, 
have shown that despite increased cytosolic DA concentrations through 
vesicular depletion, the synaptic levels of DA remained unchanged, since 
no DAT is available for transporter-mediated release. 
(Jones et al 1998) 
In vitro studies in rats demonstrated that the 5-HTT uptake blocker 
fluoxetine inhibited the calcium-independent release of 5-HT after 
MDMA/METH, demonstrating that MDMA and METH induce release of 
cytoplasmic 5-HT via 5-HTT. 
(Berger et al 1992, 
Wichems et al 
1995) 
Studies with rats demonstrated that the ability of AMPH and METH to 
release DA is directly proportional to the dose. 
(Kuczenski et al 
1995) 
In rats, METH causes dose-dependent release of DA, NA and 5-HT, and 
is more potent in the release than in the reuptake inhibition assay. 
(Rothman et al 
2000) 
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MDMA interaction with the monoaminergic system is similar to that of AMPH and 
METH, but it has more significant effects on the 5-HT system, namely, inducing the 
reverse transport of 5-HT in 5-HTT and VMAT (Baumann et al 2005, Berger et al 1992, 
Crespi et al 1997, Green et al 2003, Partilla et al 2006, Wichems et al 1995). Moreover, it 
was shown that MDMA also inhibits MAO, mainly MAO type A, the enzyme that 
preferentially degrades 5-HT. The cytoplasmatic non-vesicular stored 5-HT should, in 
normal conditions, be degraded by MAO. Therefore, as MDMA is a competitive inhibitor of 
MAO-A activity, it will contribute to the accumulation of more extracellular 5-HT (Leonardi 
& Azmitia 1994). 
In summary, amphetamines differ in their affinities for monoamine transporters, 
therefore resulting in the disruption of pathways related to different neurotransmitters. 
AMPH and METH have more potent actions on DA release rather than in 5-HT release, 
while MDMA shows greater affinity for 5-HTT over DAT. Accordingly, MDMA causes a 
higher release of 5-HT instead of DA. Importantly, AMPH, METH, and MDMA are more 
potent NA releasers, rather than DA and 5-HT (Rothman & Baumann 2003). 
 
 
1.4. Pharmacokinetics 
 
Amphetamines are weak bases with a pka around 9.9, a low molecular weight, with 
good oral bioavailability, a high volume of distribution (Vd) (around 4 L/kg), and a low 
plasma protein binding (ordinarily less than 20%). These properties enable an easy 
diffusion of these drugs across cellular membranes and lipid layers, reaching high levels 
in tissues and biological matrices with a pH lower than blood (Carvalho et al 2012, de la 
Torre et al 2004).   
 
1.4.1. Absorption  
 
AMPH is commonly consumed orally and available either as S-(+)-enantiomer (d-
AMPH) or as the racemic mixture. Pizarro and co-workers performed a study in 17 healthy 
volunteers, in which four different doses of dl-AMPH (25, 30, 35 and 40 mg) were tested. 
After AMPH administration, they found that the peak plasma concentration (Cmax) was 
attained between 2 to 3 hours (h). Moreover, when comparing area under the plasma 
concentration-time curve (AUC) over 24 h and Cmax in the range of doses administrated, 
investigators were able to conclude that plasma levels can be easily predicted, since 
variations behave in a linear mode (Pizarro et al 1999). In general, Cmax are reached 
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within 4 h after ingestion, and both AUC over 24 h and Cmax are proportional to the dose 
administered, increasing in a dose-dependent manner. Besides, it has not been reported 
significant differences of pharmacokinetic (PK) parameters between the two enantiomers 
(Carvalho et al 2012, de la Torre et al 2004). 
PK data reported for MDMA are commonly based on oral and parental 
administration. Studies showed that after a single per os (p.o.) administration of MDMA 
(50, 75, 100, 125 or 150 mg) in humans, the Cmax is reached between 1.5 to 3 h. They 
also showed that for doses of 50, 75, 100 and 125 mg, AUC over 24 h and Cmax increased 
in a dose-dependent manner (de la Torre et al 2000, Mas et al 1999). Even so and 
according to de la Torre and co-workers, for the higher 150 mg dose, the increase in 
MDMA kinetic parameters was not proportional to the dose, suggesting a non-linear PK 
(de la Torre et al 2000). The non-linear MDMA PK has been confirmed in recent studies, 
in humans and squirrel monkeys (Mueller et al 2009). 
Farré and co-workers studied MDMA PK with the successive administration of this 
drug in nine healthy male subjects, by administrating 100 mg in two doses, separated by 
an interval of 24 h. The repeated administration of MDMA led to a disproportionate 
increase in plasma concentrations, being superior than expected by simple accumulation, 
which indicated metabolic inhibition (Farré et al 2004). These observations can be related 
with the non-linear PK of MDMA in humans described above, and both can be explained 
by a possible saturation of MDMA metabolism, as well as by the inhibitory interaction of 
metabolites with some MDMA metabolizing enzymes. In vitro studies indicate that MDMA 
can act as an inhibitor of cytochrome P450 (CYP) 2D6 through a competitive interaction 
mechanism and/or by forming an enzyme metabolite complex (Carmo et al 2006, 
Delaforge et al 1999, Heydari et al 2004, Wu et al 1997). 
MDMA is commonly consumed orally and available as a racemic mixture. An MDMA 
enantioselective disposition has been reported in humans. After an oral administration of 
40 mg of MDMA racemic mixture, it was observed that the Cmax of (R)-(-)-MDMA 
enantiomer was significantly higher than the Cmax of (S)-(+)-MDMA, and the more 
pharmacologically active (S)-(+)-MDMA enantiomer was more rapidly eliminated (de la 
Torre et al 2004, Fallon et al 1999, Pizarro et al 2004). 
METH can be used p.o., intravenously (i.v.), snorted, or inhaled either through vapour 
or by the smoking of the (S)-(+)-METH hydrochloride salt. Hart et al. were able to 
conclude that after administration of intranasal METH doses, (0, 12, 25, and 50 mg / 70 
kg) the Cmax is observed after 4 h (Hart et al 2007). Schepers and co-workers performed a 
study of METH PK, administrating oral doses of 10 and 20 mg of (S)-(+)-METH to 
individuals. They conclude that the Cmax was reached between 5 to 8 h after 
administration, and that the 24 h AUC and Cmax were significantly dose-dependent 
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(Schepers et al 2003). Previous studies in humans, also showed that Cmax is attained after 
3 h by oral administration of d-METH hydrochloride (Shappell et al 1996). On the other 
hand, after i.v. administration in humans of 15 and 30 mg doses of METH, was reported 
that the Cmax was reached in 0.53 and 0.51 h (Newton et al 2005). Besides, the 
bioavailability of smoked METH (90%) is significantly superior when compared to the 
bioavailability of 67% after oral ingestion (Cook et al 1993).   
 
1.4.2. Distribution  
 
As said before, amphetamines in general have low protein binding (< 20%), which 
means that they are able to diffuse rapidly to the extracellular compartment and to every 
body tissues (de la Torre et al 2004).  
Amphetamine-dependent individuals appear to have larger Vd (6 L/kg) than drug-
naive individuals (4 L/kg). They have higher tissue affinity for the drug that leads to AMPH 
tissue sequestration, as a consequence of the development of tolerance. Protein binding 
of the two enantiomers, (S)-(+)-AMPH and (R)-(-)-AMPH, is similar, as well as their 
distribution volumes (de la Torre et al 2004).  
There is a lack of clinical studies regarding the MDMA distribution in humans after a 
controlled administration, in contrast to the various numbers of reported studies in fatal 
intoxications. It has been observed that the highest MDMA concentrations are found in the 
brain and liver, suggesting that these drugs preferentially accumulate in the referred 
organs (De Letter et al 2004, De Letter et al 2006, Garc  a-Repetto et al 2003). From the 
data reported by de la Torre et al., they established a Vd of 6.4 L/kg after the oral 
administration of 100 mg for MDMA (de la Torre et al 2004). Regarding enantiomers of 
MDMA, it was also indicated that this drug undergoes an enantioselective disposition in 
humans, since it was observed that the more pharmacologically active (S)-(+)-MDMA 
enantiomer had a higher Vd (Vd = 595 ± 204 L) than (R)-(-)-MDMA enantiomer (Vd = 383 
± 97 L) (Fallon et al 1999). 
The METH Vd is similar to that of AMPH (4 L/kg) and, according to the literature, is 
not affected by the time or route of administration (Shappell et al 1996). Volkow and co-
workers measured the whole-body distribution and bioavailability of METH in 19 healthy 
participants (nine Caucasians and ten African Americans), showing that the drug was 
distributed through several organs. METH appears to be highly accumulated in liver, 
lungs, and, in a smaller extension, in brain and kidneys. In this study the lung 
accumulation of METH was reported to be 30% higher for African Americans than 
Caucasians, though no difference was observed for the other organs (Volkow et al 2010). 
Another study showed that METH has a fast brain uptake [peak uptake at 9 minutes 
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(min)], a widespread (accumulating in cortical and subcortical areas and in white matter), 
and a long-lasting (slow clearance from brain) distribution in human brain. Besides, no 
difference among Caucasians and African Americans in METH PK and bioavailability was 
found in that study (Fowler et al 2008). Moreover, METH accumulates in saliva, hair and 
nails of drug abusers, which also has clinic and forensic interest (Cook et al 1993, Suzuki 
et al 1989).  
 
1.4.3. Metabolism 
 
Amphetamines are mainly metabolized in the liver by several enzymes. The main 
metabolic pathways of AMPH are: (1) N-deamination to phenylacetone, which is 
converted to benzoic acid by oxidation, followed by conjugation with glycine generating 
hippuric acid, capable of being excreted; and (2) aromatic hydroxylation in position four of 
the ring, resulting in 4-hydroxyamphetamine, and further conjugation of the phenol group 
with sulfate or glucuronic acid (Kraemer & Maurer 2002, Musshoff 2000) (Figure 2). 
Carvalho and co-workers reported that in the hydroxylation step, AMPH can also be 
converted to a reactive intermediate that would react with glutathione generating the 
(glutathion-S-yl)-p-hydroxyamphetamine adduct (Carvalho et al 1996). In vitro studies 
indicate that N-deamination appears to be catalysed by CYP isoenzymes of the CYP2C 
subfamily (Yamada et al 1997). On the other hand, hydroxylation of the aromatic ring 
seems to be catalysed by CYP2D6. Oxidation at the β-carbon of the side chain (aliphatic 
hydroxylation) is the minor metabolic pathway that, regarding to AMPH, leads to the 
formation of norephedrine (stereoisomer of phenylpropanolamine), followed by oxidation, 
in the aromatic ring, to hydroxynorephedrine, a compound that is implicated in the 
tolerance to peripheral actions of the drug (Lin et al 1997, Musshoff 2000) (Figure 2). 
METH is mainly metabolized through N-demethylation into AMPH, and by 4-
hydroxylation of the aromatic ring resulting in 4-hydroxymethamphetamine, that can 
undergo a further conjugation of the phenol group with sulphate or glucuronic acid (Figure 
2). Both of the metabolic pathways are catalysed by CYP2D6. Besides, the involvement of 
the genetic polymorphism associated with CYP2D6 may result in a interindividual 
variability in metabolism (Lin et al 1997). METH is also metabolized to norephedrine, and 
hydronorepherine (Caldwell et al 1972, Lin et al 1997, Musshoff 2000). Urinary levels of 
unchanged METH are much higher than of the methylenedioxy derivatives, like MDMA, 
suggesting that METH is metabolized in a lower extent (de la Torre et al 2004). According 
to Cruickshank and Dyer, METH metabolites are formed at low levels and at times where 
the acute effects are minimal, resulting in a poor contribution of metabolites to the clinical 
effects of the drug (Cruickshank & Dyer 2009) (Figure 2). 
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Figure 2 – Major metabolic pathways of amphetamine (AMPH) and methamphetamine (METH). 
 
MDMA is mainly metabolized by two pathways. Firstly, O-demethylenation of the 
methylenedioxy group occurs, resulting into a catechol N-methyl-α-methyldopamine (N-
Me-α-MeDA, 3,4-dihydroxymethamphetamine, HHMA). This step is catalysed by CYP2D6 
and, also, by CYP3A4 and CYP1A2 in humans, and by isoenzymes CYP2D1 and 
CYP3A2 in rats. That demethylenation is followed by O-methylation of one of the hydroxyl 
groups to form 4-hydroxy-3-methoxymethamphetamine (HMMA), catalysed by catechol-
O-methyltransferase (COMT). Both can be possibly conjugated with glucuronide or 
sulphate. Secondly, MDMA can be N-demethylated into 3,4-methylenedioxyamphetamine 
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(MDA), mainly mediated by CYP2B6 and also by CYP2D6, CYP1A2, and, CYP3A4 in 
humans and by CYP1A2 and CYP2D1 in rats. This step is followed by O-demethylenation 
to the catechol α-methyldopamine (α-MeDA, 3,4-dihydroxyamphetamine, HHA), and is 
catalysed by CYP2D6 and CYP3A4 in humans, and by CYP2D1 and CYP3A2 in rats. 
Lastly, α-MeDA is methylated into 4-hydroxy-3-methoxyamphetamine (HMA) by COMT. 
Both, α-MeDA and HMA can be possibly conjugated with glucuronide or sulphate (de la 
Torre et al 2005, de la Torre et al 2000, Kraemer & Maurer 2002, Segura et al 2001) 
(Figure 3). 
 
 
Figure 3 – Major 3,4-methylenedioxymethamphetamine (MDMA or ―Ecstasy‖) metabolic pathways. 
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Studies demonstrated that both catechol metabolites N-Me-α-MeDA and α-MeDA can 
be oxidized into ortho-quinones, and can conjugate with thiols and glutathione originating 
adducts (Cho et al 1999). These conjugates formation was also demonstrated in vitro in 
human liver microsomes, by Easton et al. (Easton et al 2003). Conjugates are formed in 
the liver, but can be distributed to other organs, namely, to the brain. That was 
demonstrated by an in vivo study where metabolites were measured in the rat brain 
(Jones et al 2005). 
 
1.4.4. Excretion 
 
Amphetamines plasma half-life is highly dependent on the urine pH, since the major 
elimination route is the renal excretion. As weak bases, amphetamines renal excretion is 
increased by urinary acidification and decreased by urinary alkalinisation. For these 
reason, some amphetamines consumers ingest bicarbonate, so they can increase the 
amphetamines plasma half-life, prolonging the drug‘s effect (Cook et al 1993, Quinn et al 
1997). The elimination half-life tends to be longer in users dependent of AMPH and METH 
and in individuals with alkaline urine (de la Torre et al 2004). Data obtained by Poklis et al. 
demonstrated that about 35 to 44% of AMPH is excreted over 24 h. They also reported 
that elimination of AMPH increases with increasing urine flow and decreasing urine pH 
(Poklis et al 1998). 
MDMA elimination half-life is between 6 to 9 h, and the majority of the dose is 
excreted in the 24 h following administration. Most MDMA (80%) is metabolized through 
the liver, and around 20% is excreted with no changes in urine. Besides, the urinary 
elimination is independent of the doses administrated, while non-renal elimination appears 
to be dose-dependent (de la Torre et al 2004, Fallon et al 1999). 
Segura et al. reported that the major MDMA metabolite excreted in urine is HMMA 
(22.7% of the dose), and N-Me-α-MeDA the second with a 17.7% of the total MDMA dose 
recovery (Segura et al 2001). MDMA elimination in humans is stereoselective, and the 
more pharmacologically active (S)-(+)-MDMA enantiomer has a shorter half-life (3.6 ± 0.9 
h) than the less active (R)-(-)-MDMA enantiomer (5.8 ± 2.2 h) (Fallon et al 1999). 
METH is mainly excreted (70% of METH dose) in urine within 24 h after 
administration. Also, 50% of the METH dose is eliminated unchanged, 15% as the 4-
hydroxymethamphetamine, and 10% as AMPH. The percentage of METH excreted 
unchanged in urine decreases with increasing doses, which can be explained by a lower 
elimination rate or an increasing in non-renal elimination for higher doses (Carvalho et al 
2012, Cook et al 1993). 
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1.5. Acute effects in laboratory animals and humans 
 
1.5.1. Laboratory animals 
 
The acute effects of amphetamines in laboratory animals include mainly hyperthermia 
and hyperlocomotion. These effects are due to the high release of monoaminergic 
neurotransmitters and the interaction with the specific pre- and postsynaptic receptors 
(Carvalho et al 2012).  
Randrup and Munkvad reported the behaviour of rats, mice, guinea-pigs, cats and 
squirrel monkeys after the subcutaneous (s.c.) administration of AMPH. All animals 
performed stereotyped activity. Rats, mice and guinea-pigs presented similar stereotyped 
sniffing, licking, and biting activity, and in the initial and final phase after the injection was 
also reported increased locomotion. Cats presented stereotyped head movements, and 
the squirrel monkeys all performed stereotyped activity, but with individual differences. 
The behaviour reported for rats was also produced after METH administration (Randrup & 
Munkvad 1967). 
Researchers have studied the DA neurotransmission influence on amphetamine 
actions, due to its involvement in locomotion, cognition, affect, and neuroendocrine 
functions. Giros and co-workers showed that AMPH promotes locomotor activity due to its 
action on DAT, once in mice lacking this transporter, the drug had no effect on locomotor 
activity or DA release and uptake. They also demonstrated that DAT is the main 
transporter that mediates hyperlocomotor effects of AMPH (Giros et al 1996). Kuczenski 
and Segal studied in rats the temporal and dose-related behavioural and striatal 
monoamine response to AMPH and observed that: (1) a significant relationship between 
the magnitude and duration of DA release and the increases in behavioural response 
occurred, (2) the presence of stereotyped movements was not dependent on the quantity 
of striatal DA, and (3) some of the behavioural responses were related to changes in 
striatal 5-HT concentrations. These data suggested that the behavioural response to 
AMPH might be related with levels of both DA and 5-HT release (Kuczenski & Segal 
1989). Studies in rats also showed that METH is capable of increasing locomotor activity 
due to the dopaminergic transmission (Wallace et al 1999).  
Several studies in rats showed that MDMA also produces an hyperlocomotor 
response due to the release of 5-HT in several brain regions, in a dose-dependent 
manner (McNamara et al 1995, Shankaran & Gudelsky 1999, Souza et al 1997, 
Yamamoto & Spanos 1988). In addition to the hyperlocomotion, it was also reported the 5-
HT syndrome, as a result of excessive 5-HT release. The criteria used to determine the 
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presence of the 5-HT syndrome in rats is usually based in stereotyped motor behaviours 
as low body posture, forepaw treading, head weaving, hind limb abduction, piloerection, 
ejaculation, salivation, followed by dose-dependent convulsions, and possible death 
(Morley et al 2005, Piper et al 2005, Shankaran & Gudelsky 1999, Souza et al 1997, 
Spanos & Yamamoto 1989). Callaway and colleagues demonstrated that MDMA 
produced a dose-dependent increase in rat locomotor activity, due to 5-HT release. They 
stated that pre-treatment with fluoxetine (a 5-HT uptake inhibitor) inhibited MDMA-induced 
locomotor hyperactivity, whereas it failed to affect the AMPH-induced hyperactivity. These 
data suggested that AMPH and MDMA produced locomotor activity by different 
mechanisms, possible due to the affinity of the drugs to the different drug transporters 
(Callaway et al 1990).  
One of the most dangerous acute effects of amphetamines is hyperthermia, and the 
most studied amphetamine in this subject is MDMA. Several studies demonstrated that 
MDMA causes a dose-dependent hyperthermia in various laboratory animals, such as 
mice, rats, rabbits, guinea pigs, and pigs (Capela et al 2009). Colado and co-workers 
demonstrated in Lister Hooded rats that an intraperitoneal (i.p.) administration of MDMA 
(20 mg/kg) induced hyperthermia with a temperature increase of approximately 2.5ºC, that 
continued for 3 h (Colado et al 1993). Carvalho and colleagues reported an hyperthermic 
response in mice, after an i.p. injection of MDMA (5, 10, or 20 mg/kg), potentiated by high 
ambient temperature, since at an ambient temperature of 30 ± 2ºC, the maximum 
increases were higher than the maximum temperature reached at an ambient temperature 
of 20 ± 2ºC. MDMA increased mice body temperature, with a maximum at approximately 
30 min after injection, and remained for more than 4 h. Besides, the hyperthermic 
response induced was dependent on MDMA doses, with a largest change of 
approximately 2ºC at the highest dose (20 mg/kg) (Carvalho et al 2002). Researchers also 
demonstrated that MDMA administration in rats produced hypothermia at an ambient 
temperature of 15ºC, and hyperthermia at 19ºC or 30ºC (Green et al 2005, Green et al 
2004b). Gordon and co-workers studied the MDMA effects on temperature regulation, and 
observed that the metabolic rate, evaporative water loss, motor activity, and colonic 
temperature were augmented and were related to ambient temperature (Gordon et al 
1991). Yehuda and Wurtman also reported hyperthermia after AMPH administration in 
rats kept at ambient temperature of 20ºC and 37ºC and hypothermia in a ambient 
temperature range of 4 – 15ºC (Yehuda & Wurtman 1972). 
The increase in temperature produced by MDMA has been attributed to 5-HT, 
although, recent studies showed that hyperthermia may be related with the activation of 
postsynaptic DA D1 receptors that occurs after DA release (Baumann et al 2007). Studies 
in mice and rats, regarding the hyperthermia induced by amphetamines (MDMA and p-
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cloroamphetamine), and using 5-HT1/2, 5-HT2A, and 5-HT2C antagonists, and 5-HT uptake 
inhibitors, demonstrated that treatment with these agents failed to alter the course of the 
hyperthermia promoted by amphetamines. Moreover, the DA D1 receptors antagonists 
were able to antagonize hyperthermia, contrarily to the DA D2 receptor antagonist. These 
results suggested that the DA release and activation of DA D1 receptor are important to 
hyperthermia induced by those amphetamines (Mechan et al 2002b, Sugimoto et al 
2001). 
After administration of METH (2.5, 5.0, 7.5 mg/kg) to rats at an ambient temperature 
of 21 ± 1ºC, it has been reported a significant increase in body temperature at 21ºC, in 
which the maximum core temperature increase ranged from 0.92 to 1.51ºC. They also 
reported a decrease in body temperature at an ambient temperature of 7ºC, in which the 
obtained decrease ranged from 2.22 to 4.15ºC lower than the initial body temperature. 
These results suggest that METH is also capable of inducing hyperthermia, and at low 
environmental temperature may generate hypothermia (Mohaghegh et al 2002).  
 
1.5.2. Humans 
 
Amphetamines are able to generate a large variety of acute clinical effects by 
modulating peripheral and central monoamine neurotransmitter function. Amphetamines 
cause CNS stimulation, producing effects as euphoria, arousal, enhanced mood, well-
being, increased alertness, wakefulness and concentration, reduced appetite and fatigue, 
insomnia, behavioural disinhibition, and MDMA users particularly report feelings of 
increased closeness to others, greater sociability, and heightened sensory perception 
(Cretzmeyer et al 2003, Cruickshank & Dyer 2009, Derlet et al 1989, Hart et al 2001, 
Johanson & Uhlenhuth 1980, Liechti et al 2000, Vollenweider et al 1998). 
The peripheral effects of amphetamines seem to be caused by indirect 
sympathomimetic stimulation, resulting in an increased energy, psychomotor activation, 
restlessness, elevated body temperature (hyperthermia), increased blood pressure 
(hypertension), increased heart rate (tachycardia), increased respiration rate, palpitations, 
pupil dilatation (mydriasis), tremor, sweating (diaphoresis), jaw clenching (bruxism), dry 
mouth (xerostomia) and hyperreflexia (Cohen & Cocores 1997, Cruickshank & Dyer 2009, 
Derlet et al 1989, Greene et al 2008, Liechti et al 2000, Vollenweider et al 1998). 
A study on the effects of intranasal METH administration in humans showed that the 
cardiovascular effects (heart rate and blood pressure) and the subjective effects described 
by the users, like ―good drug effects‖ and ―stimulated‖, increased in a dose-dependent 
manner (Hart et al 2007). Mas and co-workers reported that AMPH and MDMA were able 
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to increase blood pressure and heart rate, when compared with placebo, after 
administration in humans (Mas et al 1999). 
One of the most dangerous acute effects of amphetamines is hyperthermia. Both 
METH and MDMA have been implicated in fatalities related with this physiological effect. 
As already mentioned, MDMA is the most studied drug, and there have been reported 
body temperatures of about 43ºC (Green et al 2004a, Jaehne et al 2007). This drug is 
frequently used recreationally in popular ―rave‖ parties or nightclubs where elevated 
ambient temperature, crowded rooms, physical exertion (dancing), and dehydration are 
common and can contribute to an elevated body temperature (Henry 1992, Irvine et al 
2005, Patel et al 2005). Accordingly, factors as repetitive physical activity, peripheral 
vasoconstriction, loss of thermoregulatory mechanisms at the CNS, loss of body signal 
perception (like thirst and exhaustion), euphoria, increased muscle tone, and heat 
production are the factors that mainly contribute to hyperthermic effects associated with 
MDMA use (Capela et al 2009). 
A study under two different ambient temperatures, 30ºC and 18ºC, in ten healthy 
recreational MDMA users, reported that this drug produced increases in body 
temperature, blood pressure, heart rate, and subjective effects. After MDMA, the 
increased body temperature was significant in either warm or cold environments, but the 
temperatures reached were higher in the warm environment. The increase in body 
temperature was higher under warm condition but it did not reach statistically significance, 
once under the placebo conditions an elevation in temperature under the warm 
environment was also reported (Freedman et al 2005). Another study in individuals who 
participated in ―raves‖ and were MDMA users evaluated their physiological parameters 
before and after a dance party. Those with the highest MDMA plasma concentrations 
reported moderate increases in blood pressure, heart rate and body temperature after 
drug use at the dance party (Irvine et al 2005). 
Furthermore, hyperthermia induced by amphetamines can lead to fatal 
consequences, as rhabdomyolysis, acute renal failure, disseminated intravascular 
coagulation (DIC), and multiple organ failure (Henry 1992, Kalant 2001, Kendrick et al 
1977). 
Amphetamines can also induce unpleasant CNS symptoms. It has been reported in 
several studies symptoms such as anxiety, insomnia, hallucinations (sound and visual 
hallucinations), irritability, mental confusion and panic attacks. The psychological side 
effects related with the use of these drugs can also lead to depression, paranoia, violent 
behaviour, memory lapses, flashbacks, cognitive deficits, and suicidal ideation (Cole & 
Sumnall 2003, Davison & Parrott 1997, Degenhardt & Topp 2003, Derlet et al 1989, 
Sommers et al 2006). When comparing the psychological side effects of crystal METH 
Part I: Introduction 
18 
with those of AMPH, researchers observed that the prevalence of panic attacks among 
crystal METH users was higher than in AMPH users (20% vs. 9%), although the 
prevalence in terms of violent behaviour (43% vs. 24%) and hallucinations (46% vs. 20%) 
was respectively higher among AMPH users than in METH (Degenhardt & Topp 2003). 
According to the Davinson and Parrot study, the duration of effects like insomnia, 
irritability, depression and paranoia varied, depending on the individuals, from a few hours 
to over a day (Davison & Parrott 1997). Moreover, AMPH use can lead to delirium, 
convulsions, acute panic disorder, psychosis, arrhythmia, ischemic and haemorrhagic 
stroke, acute renal failure, rhabdomyolysis, DIC, hepatic necrosis, hyponatremia, multi-
organ failure, coma, and, in a worst case scenario, it can lead to sudden death (de la 
Torre et al 2004, Hall & Henry 2006, Henry 1992, Kendrick et al 1977). In MDMA use 
commonly emerges another acute effect named 5-HT syndrome. This syndrome shows 
similarity to the acute hyperthermia and multi-organ failure events, and it‘s characterized 
by having a rapid onset, associated with confusion, diaphoresis, diarrhoea, cardiovascular 
instability, and increased muscle tone and rigidity that can lead to dead (Hall & Henry 
2006). 
Table 2 presented below summarizes the desired effects of consuming 
amphetamines, as well as the most relevant adverse effects and toxicity observed. 
 
Table 2 – Desired, adverse effects, and acute toxicity of amphetamines use. 
 
  
Desired effects 
Adverse 
physiological 
effects 
Adverse 
psychological 
effects 
Acute toxicity 
 
 Euphoria 
 
 Energy 
 
 Arousal 
 
 Well-being 
 
 Behavioural 
disinhibition 
 
 
 Concentration 
 
 Greater 
sociability 
 
 Increased 
closeness to 
others 
 
 
 Hyperthermia 
 
 Hypertension 
 
 Tachycardia 
 
 Mydriasis 
 
 Diaphoresis 
 
 Bruxism 
 
 Xerostomia 
 
 Headaches 
 
 Ataxia 
 
 
 Anxiety 
 
 Insomnia 
 
 Panic attacks 
 
 Mental 
confusion 
 
 Irritability 
 
 Hallucinations 
 
 Paranoia 
 
 Psychosis  
 
 Suicidal 
ideation 
 
 
 Rhabdomyolysis  
 DIC 
 
 Hepatotoxicity 
 
 Cardiotoxicity 
 
 Nephrotoxicity 
 
 Teratogenic 
effects 
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1.6. Evidences of neurotoxicity 
 
1.6.1. Laboratory animals in general  
 
The potential neurotoxic effects of amphetamines have been immensely studied 
proving their ability to damage brain monoaminergic cells, namely by causing long-term 
deficits in dopaminergic and serotoninergic systems in several brain areas (Commins et al 
1987, Gibb et al 1997, Ricaurte et al 1982, Schmidt 1987, Sonsalla et al 1996, Villemagne 
et al 1998). Importantly, the neurotoxic actions of amphetamines have been evaluated by 
biochemical (decreased levels of monoamines and their major metabolites, decrease of 
monoamine transporter binding sites, and lower expression and/or activity of enzymes 
involved in synthesis and metabolism of neurotransmitters), histological, and 
immunocytochemical techniques (Carvalho et al 2012).  
One of the major neurotoxic actions of amphetamines seen in laboratory animals is 
the sustained depletion of monoamine brain levels. A study in mice clearly proved this 
neurotoxic action, after the administration of (+)-AMPH (6.3, 12.5, 25, 37 or 62 µg/h) by 
means of osmotic mini pumps, placed subcutaneously, for two to seven days, where 
animals were sacrificed eight days after starting the treatment. It was described a 
reduction of NA levels for AMPH infusion of 62 µg/h in several brain areas, and, also, 
depletion of DA levels for AMPH infusions of 25, 37 and 62 µg/h in the olfactory tubercle 
and striatum, in a dose-dependent manner (Jonsson & Nwanze 1982).  
MDMA also exhibits the ability of depleting monoamine neurotransmitter content in 
the rat‘s brain. Several studies reported depletion in brain 5-HT levels after MDMA 
administration (Aguirre et al 1998a, Colado et al 1993, Colado et al 1995, Commins et al 
1987, O'Shea et al 1998, Schmidt 1987, Shankaran & Gudelsky 1999). In fact, Schmidt 
demonstrated that the 5-HT depletion caused by 10 mg/kg, s.c. administration, of MDMA 
has two distinguishable phases. The first one appears to produce a reversible depletion of 
5-HT, in which 5-HT concentrations declined to 16% of control, 3 h after administration. 
Following this initial decline, occurred a recovery of 5-HT levels, returning to basal levels, 
between 6 and 24 h. The second phase is characterized by another 5-HT depletion in the 
days following MDMA administration: after a week the 5-HT levels declined to 74% of 
control (Schmidt 1987).  
METH also causes severe depletion in brain monoamine levels. The repeated s.c. 
administration of high doses of METH (50 and 100 mg/kg, twice daily, for four days) to 
rats resulted in a dose-related decrease in DA levels and its uptake sites in the striatum, 
two weeks after the last administration period. No changes in brain NA levels were 
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reported after this regimen of repeated METH administration when compared to controls 
(Wagner et al 1980). 
Relevant studies regarding the ability of AMPH, MDMA, and METH to deplete 
monoamine neurotransmitter content, after administration to laboratory animals, are 
summarized in Tables 3, 4, and 5, respectively. 
The neurotoxic action of amphetamines can also be related with the degeneration of 
neuronal fibres. A study in mice demonstrated, histochemically, that the continuous 
infusion of large doses of (+)-AMPH (25 or 37 µg/h) for seven days, by means of osmotic 
minipumps, led to a dose-dependent and long-lasting reduction of DA nerve terminals until 
eight weeks after the last (+)-AMPH infusion. The results also suggest that with time there 
was a slow regeneration of DA nerve terminals (Jonsson & Nwanze 1982). MDMA was 
also shown, in several studies, to be able to promote damage to the nerve terminals 
(Commins et al 1987, O'Hearn et al 1988, O'Shea et al 1998, Schmidt 1987). By using an 
immunocytochemical technique, O‘Hearn and colleagues were able to demonstrate the 
structural damage to the terminal portions of axons, promoted by MDMA, in rats. Two 
weeks after the administration of MDMA (20 mg/Kg, s.c., twice a day for four days) 
fragmented 5-HT axons were observed in the forebrain. These fragmented axons are an 
anatomic evidence for the degeneration of 5-HT projections (O'Hearn et al 1988). METH 
was also shown to induce terminal degeneration in laboratory animals. Ricaurte and co-
workers reported that METH (3 x 50 mg/kg, s.c., every 8 h) induced destruction of DA 
terminals, along with correlative DA neurochemical deficits in the striatum and nucleus 
accumbens of rats, even three weeks after the administration (Ricaurte et al 1982). 
Several relevant studies related with the degeneration of neuronal fibres induced by 
AMPH and MDMA are summarized in Tables 3 and 4, respectively. 
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Table 3 – Relevant studies related to the neurotoxicity of AMPH to laboratory animals. 
Dosage 
Regimen 
Relevant studies  Reference 
17 mg/kg, s.c., 
twice daily 
Repeated injections of d-AMPH to rats resulted in the 
decrease of brain NA levels. These effects persisted for 
several days after the last injection of the drug. 
(McLean & 
McCartney 
1961) 
10 mg/kg, s.c., 
twice daily, 2 h 
interdose interval 
A study in rabbits demonstrated a reduction in NA levels 
in the superior cervical ganglia and in the brain, 4 h after 
the first administration of d-AMPH to the referred animals. 
(Sanan & 
Vogt 1962) 
9.2 mg/kg, i.p., 
single dose 
A single injection of d-AMPH administered to rats pre-
treated with iprindole (interferes with the metabolism of 
AMPH and prolongs its half-life) resulted in the 
destruction of DA nerve terminals, two weeks after the 
treatment. 
(Ricaurte et 
al 1984) 
0.1 or 0.25 mg/kg, 
s.c., twice daily, for 
5 days 
Prolonged exposure of rats to AMPH at doses near 
threshold for locomotor activation, and within the 
therapeutic range for attention deficit hyperactivity 
disorder (ADHD) treatment, can produce sensitization-like 
effects on the locomotor response to a subsequent 
exposure. Four days after the last treatment, animals 
received another 0.5 mg/kg of AMPH, which promoted a 
marked increase in locomotor response. 
(Kuczenski & 
Segal 2001) 
1, 2 or 3 mg/kg, 
every other day 
A study on the performance of rats with a repeated 
intermittent administration of AMPH showed that the 
effects of repeated administration of the drug may 
interfere with cognitive processes, once a 
psychostimulant-sensitization can lead to attentional 
consequences. There were increases in the number of 
false alarms, like ―claims‖ for hits in non-signal trials, 
suggesting possible hyper attentional dysfunctions that 
may contribute to the development of psychotic 
symptoms. 
(Deller & 
Sarter 1998) 
0.1-1.0 mg/kg, 
intramuscular 
(i.m.), twice daily, 
for 6 or 12 weeks 
A research in rhesus monkeys reported that the AMPH-
sensitized monkeys were deeply impaired in their ability 
to acquire cognitive tasks, since several months after the 
treatment with AMPH, the monkeys had profound and 
enduring deficits in the acquisition of a spatial working 
memory task, and spatial delayed response. 
(Castner et al 
2005) 
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Table 4 – Relevant studies related to the neurotoxicity of MDMA to laboratory animals. 
Dosage 
Regimen 
Relevant studies  Reference 
10, 15 or 20 
mg/kg, i.p., single 
dose 
A single dose of MDMA resulted in significant loss of 
5-HT and decreases in the 5-HT major metabolite, 5-
hydroxyindoleacetic acid (5-HIAA) in rats‘ brain, 
seven days after the administration of 10 or 15 mg/kg, 
or four days after 20 mg/kg. 
(Colado et al 1993, 
Colado et al 1995, 
O'Shea et al 
1998). 
10 mg/kg x 4, 
i.p., every 2 h 
A study in rats reported a 45% depletion of 5-HT 
levels one week after several doses of MDMA. 
(Shankaran & 
Gudelsky 1999) 
10, 20 or 40 
mg/kg, s.c., twice 
daily, for 4 days; 
or 40 mg/kg, s.c., 
single dose 
Commins and co-workers reported in rats depletions 
of 5-HT after repeated injections of MDMA and, also, 
after a single administration of a higher dose of the 
drug, two weeks after exposure to MDMA. It was also 
observed nerve terminal degeneration in the striatum. 
(Commins et al 
1987) 
5 mg/kg, s.c., 
twice daily for 4 
days 
In a study performed in squirrel monkeys, researchers 
injected the animals with MDMA and observed the 
reduction of brain serotonergic innervations, and 5-HT 
levels. The serotonergic innervations still remained 
reduced seven years after exposure to the drug, 
showing that the damage to serotonergic system is, 
probably, irreversible. 
(Hatzidimitriou et 
al 1999) 
10, 15, 20 mg/kg, 
i.p., twice daily, 
for 3 days 
After a neurotoxic exposure of rats to MDMA, it was 
reported a long lasting cognitive impairment over the 
16 days following the exposure. 
(Marston et al 
1999) 
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Table 5 – Relevant studies related to the neurotoxicity of METH to laboratory animals. 
Dosage 
Regimen 
Relevant studies  Reference 
10 mg/kg x 4, 
i.p., very 2 h 
Rats treated with a neurotoxic regimen of METH, 
presented a reduction of DA contents in caudate nucleus 
(56%) and nucleus accumbens (30%) one week later. The 
levels of 5-HT were also decreased in caudate nucleus 
(50%) and nucleus accumbens (63%). 
(Wallace et al 
1999) 
10 or 20 mg/kg 
x 4, i.p., every 
2 h 
A study in mice demonstrated a marked depletion 
of striatal DA (≥ 90%) seven to eight days after METH 
administration. 
(Sonsalla et al 
1996) 
1.25 mg/kg, 
p.o., given 
twice, 4 h apart 
A study in squirrel monkeys treated with METH reported 
decreases in striatal dopaminergic markers one week after 
treatment. Moreover, the study was conducted in two 
different AT (26 and 33ºC), and the ones treated at the 
highest AT had the largest dopaminergic deficits. 
(Yuan et al 
2006) 
0.2 mg/kg or 2 
x 2 mg/kg, i.m., 
24 h apart 
Studies with vervet monkeys demonstrated that after a 
long-term exposure to METH there is a decrease in 
phenotypic markers of the DA system. Decreases in 
striatal DA content were reported, as well as decreases in 
DAT, TH, and VMAT. 
(Harvey et al 
2000, Melega et 
al 2007) 
 
 
In addition to the damage to dopaminergic and serotoninergic neuronal systems, 
amphetamines can also induce neuronal death. Using a terminal deoxynucleotidyl 
transferase-mediated biotin-dUTP nick-end labelling (TUNEL) histochemical method to 
verify DNA fragmentation, Krasnova and co-workers reported that the i.p. administration of 
AMPH (10 mg/kg, four times, every 2 h) in mice resulted in the death of non-dopaminergic 
cells in the striatum, the maximal cell death occurring four days after AMPH injections 
(Krasnova et al 2005). In several studies, MDMA administration to mice and rats produced 
neuronal death in several brain areas including the cortex, hippocampus, amygdala, 
ventromedial/ventrolateral thalamus, and tenia tecta (Armstrong & Noguchi 2004, 
Commins et al 1987, Meyer et al 2004, Schmued 2003, Tamburini et al 2006, Warren et al 
2007). METH-induced neuronal death was also investigated in the brain of mice and rats, 
and it was observed in several areas, namely the striatum, cortex, hippocampus, indusium 
griseum and medial habenular nucleus (Armstrong & Noguchi 2004, Deng et al 2001, 
Warren et al 2007, Zhu et al 2006). Corroborating these in vivo findings, several in vitro 
studies demonstrated that AMPH, METH and MDMA induced neuronal apoptosis in 
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cultured neurons of the rat cortex and in cerebellar granule neurons (Capela et al 2007b, 
Capela et al 2006a, Capela et al 2006b, Jiménez et al 2004, Stumm et al 1999). 
The neurotoxic actions of amphetamines were also reported in non-human primates. 
One example of a study that report these findings was conducted by Scheffel and co-
workers, in which 5 mg/kg MDMA was injected to baboons, s.c., twice a day, for four days, 
and animals were sacrificed 13, 19 and 40 days, or 9 and 13 months after the last dose of 
the drug. In experiments conducted for short periods after the treatment with MDMA (13 to 
40 days) a substantial loss of 5-HTT was observed in all areas of the brain examined. 
Meanwhile, 9 and 13 months after administration, this loss was only reported in 
neocortical areas. In fact, no reductions of 5-HTT were observed in the hypothalamus and 
midbrain, between 9 and 13 months after MDMA, and there was a recovery and an 
increase in the binding sites when compared to controls (Scheffel et al 1998). Other 
relevant studies related with the neurotoxic actions of AMPH, MDMA and METH in non-
human primates are summarized in Tables 3, 4 and 5, respectively.  
Regarding long-term behavioural changes, several reports were published in ATS. 
Segal and Kuczenski observed that a repeated exposure to AMPH [2.5 or 4.0 mg/kg, s.c., 
multiple runs (four injections a day at 2 h intervals)] resulted in an increase in the 
magnitude of post-stereotypy locomotor activation with a continuous state of extreme 
agitation, as seen by the locomotor response pattern to the 4th injection of the 15th run. 
Additionally, after a challenge with 2.5 mg/kg of AMPH, three days after the last injection 
of 15th run of the drug, a persistent MDMA-induced behavioural pattern (like nose-poking) 
occurred, and the post-stereotypy locomotion remained elevated (Segal & Kuczenski 
1997).  
MDMA can also affect the experimental animal‘s cognitive function. Spanos and 
Yamamoto reported that after repeated injections of MDMA (2.5, 5.0, and 7.5 mg/kg, i.p.) 
to rats, the stereotypic locomotor behaviour and the serotonin syndrome were augmented, 
which suggest that, like AMPH, MDMA can produce behavioural sensitization (Spanos & 
Yamamoto 1989). A long-term effect of MDMA exposure (three to four weeks after the 
administration) is the decrease in social interaction, contrarily to MDMA acute effects that 
induce increase sociability (Bull et al 2003, Clemens et al 2004, Fone et al 2002). Other 
studies in rats also report that MDMA induces long-term and persistent anxiety-like 
behaviours (Baumann et al 2007, Bull et al 2004, Clemens et al 2004). 
METH is also known to interfere with animal behaviour. Segal and Kuczenski 
observed that a subsequent repeated exposure to METH (2.5 or 4.0 mg/kg, s.c., four daily 
injections, 2 h apart) led to an increase in the magnitude of post-stereotypy locomotor 
activation, and that the METH response seems to be markedly longer than the AMPH 
response in male Sprague-Dawley rats (Segal & Kuczenski 1997). Besides, a neurotoxic 
Part I: Introduction 
25 
regimen with METH can also induce impairment of working memory, both spatial and non-
spatial working memory in rats (Nagai et al 2007, Schröder et al 2003). Decreased social 
interaction and increased anxiety were reported after METH exposure in either Wistar rats 
and Vervet Monkeys (Clemens et al 2004, Melega et al 2007). In Tables 3 and 4 are 
presented relevant studies related with changes in animal‘s behaviour and cognitive 
function induced by AMPH and MDMA, respectively. 
 
1.6.2. Adolescent animals 
 
Amphetamines are commonly used as illicit recreational drugs by many teenagers 
and young adults and several studies showed that it can greatly affect their cognitive 
skills, during their lifetime (King et al 2010, Kish et al 2010, McCann et al 1999). The 
prevalence of amphetamines usage is higher in adolescents and young adults (EMCDDA 
2014), and therefore there is an increased need for performing more studies regarding the 
consequences of exposure to these drugs during the adolescent period (Spear 2000). For 
that reason, researchers mimic the exposure of human adolescents by conducting 
experiments with laboratory animals from that developmental period.  
Adolescence is characterized by neurobiological processes that influence behaviour 
and abilities during adulthood. The use of amphetamines sometimes starts in this 
developmental period, and the early use of these drugs has been found to predict the 
development of drug abuse issues and mood disorders in adulthood (Chambers et al 
2003, Chen et al 2009, Laviola et al 1999, Spear 2000). The neurological alterations after 
ATS misuse in adolescence have been proven in animal studies, as it will be detailed 
bellow. 
AMPH is commonly used in humans in the therapy for attention deficit hyperactivity 
disorder (ADHD), a disease that specially affects children and adolescents (Kutcher et al 
2004). Despite many years of therapeutic experience with this drug, concerns are still 
raised regarding the possible neurotoxic effects that could occur when it is chronically 
used. Soto and co-workers performed a study in peri-adolescent rhesus monkeys and the 
cognitive, behavioural, physiological and in vivo neurochemical parameters were 
assessed. For 18 months, the juvenile male monkeys (24 months of age) received a 
methylphenidate solution (12 to 16 mg/kg) or a dl-AMPH mixture (0.7 to 0.8 mg/kg), with 
doses comparable to the therapeutic levels used in children, twice daily, seven days a 
week. Researchers found no differences to control animals concluding that 
methylphenidate and AMPH have a reduced effect on cognitive, behavioural or 
physiological development on peri-adolescent non-human primates, when administered in 
a therapeutic range (Soto et al 2012). Importantly, the animal model used in that study, 
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the juvenile male monkeys, had no ADHD contrarily to the children and young adults that 
need this therapy. Nonetheless, this laboratory study argues for the safety of these drugs 
in the clinical treatment of ADHD. 
AMPH doses (0.5, 1.5, or 5.0 mg/kg, i.p.) were given daily to adolescent Sprague-
Dawley rats models from postnatal day (PND) 30 to PND 50 and the behavioural profile 
and electrophysiological properties of midbrain monoaminergic neurons were assessed 
later during adulthood (between PND 71 and PND 85) under drug-free conditions 
(Labonte et al 2011). The middle dose of AMPH (1.5 mg/kg) produced an increase in 
extracellular levels of 5-HT and DA in adulthood, in contrast to the highest AMPH dose 
(5.0 mg/kg) that augmented the extracellular levels of NA, but not 5-HT or DA levels, 
when evaluated between PND 71 and PND 85. In addition, the adolescent AMPH 
exposure also induced a hyperlocomotion response between PND 71 and PND 85 in rats 
treated with 1.5 mg/kg dose, and all the three doses promoted more risk in drug-taking 
behaviours during adulthood. These results suggest that AMPH exposure during 
adolescence may promote long-lasting neurophysiological alterations that influence their 
future behaviour (Labonte et al 2011).  
Adolescents are particularly susceptible to drug-induced neuroadaptations and 
cognitive changes, since their brain is still under development and undergoing anatomic 
and functional changes (Andersen et al 2002, Smith 2003). A recent study performed the 
administration of AMPH (1 or 3 mg/kg, i.p., one injection every other day) to adolescent 
rats from PND 37 to PND 55 and to adult rats from PND 98 to PND 116. This regimen 
induced long-lasting consequences on drug sensitivity and cognitive functions to 
adolescent rats (Sherrill et al 2013). Adolescents were less sensitive to psychomotor 
effects of AMPH and more vulnerable to exposure-induced cognitive impairments, when 
compared to adult rats. The results demonstrated that the effects of AMPH in cognitive 
function depend on the age of exposure, and suggest that adolescent rats are more 
susceptible to amphetamine-induced neurobehavioral deficits (Sherrill et al 2013).  
A study examined the reinforcing properties of AMPH (0, 1, 3.3, or 10 mg/kg, i.p.) in 
developing mice on PND 14 to 17, 21 to 24, or 28 to 31 (Cirulli & Laviola 2000). The 
results indicated that AMPH-induced conditioned place preference was developed early, 
considering that mice were able to acquire a place preference that relied on adult-like 
sensory, motor and associative capabilities. Moreover, this conditioned-place preference 
appeared earlier in females than in males. Also, AMPH increased, in a dose-dependent 
fashion, the locomotor activity and females were also more sensitive when compared to 
males. Females increased sensitivity to the locomotor activity effects of AMPH occurred 
between PND 14 and 21, with no significant changes at PND 21 and 28. The results 
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suggest that AMPH-induced changes in adolescent mice seem to depend on gender and 
age of exposure (Cirulli & Laviola 2000).  
McPherson and Lawrence performed a study in adolescent (PND 33 to 41) Sprague-
Dawley rats, which were exposed to i.p. injections of 2 mg/kg or 10 mg/kg of AMPH, once 
daily, for ten days, followed by a four week period of abstinence and a subsequent 
rechallenge with AMPH (1.5 mg/kg, i.p.) (McPherson & Lawrence 2006). The exposure to 
AMPH during the adolescence period promoted behavioural sensitization to an AMPH 
rechallenge in adulthood. The rechallenge with AMPH promoted a higher neuronal 
activation in rats that were exposed previously to 10 mg/kg of AMPH when comparing to 
those exposed previously to 2 mg/kg. Nevertheless, the sensitized locomotor activity was 
similar between the two groups. The researchers concluded that the adolescent exposure 
to AMPH led to sensitization in adulthood accompanied by a widespread neuronal 
activation (McPherson & Lawrence 2006). 
In summary, it may be postulated that, in healthy animal models, AMPH impairs 
neurological functions. With that being said, it would be extremely useful to ascertain 
whether in a juvenile animal model of ADHD, the AMPH neurotoxicity would occur in the 
same fashion as observed in healthy adolescent animals.  
As mentioned previously in this thesis, MDMA induces neurotoxicity in adult animals, 
with reductions in the biochemical 5-HT markers, including depletion on the levels of 5-HT 
and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), lower 5-HTT density and 
decreased activity of tryptophan hydroxylase (TPH), the 5-HT rate-limiting synthesis 
enzyme (Capela et al 2009, Lyles & Cadet 2003, Ricaurte et al 2000).  
Several studies indicate that perinatal or neonatal exposure to MDMA causes less 
neurotoxic effects than in adult animals (Aguirre et al 1998b, Colado et al 1997, Kelly et al 
2002, Klomp et al 2012, Meyer & Ali 2002, Meyer et al 2004). A neurotoxic dose of MDMA 
(4 x 10 mg/kg, i.p., every 2 h) given to adolescent rats on PND 45, induced hyperthermia 
in the day of the experiment and, two weeks after the exposure, researchers observed 
lipid and protein peroxidation, mitochondrial DNA deletion and subsequent impaired 
expression of subunits of the mitochondrial complexes I (NADH dehydrogenase) and IV 
(cytochrome c oxidase). These are essential complexes of the mitochondrial respiratory 
system required for energy production, and therefore these alterations may cause long-
term impairment in brain‘s mitochondria (Alves et al 2007). Rats pre-treated with selegiline 
(2 mg/kg, i.p.), a MAO-B inhibitor, had no changes in the hyperthermic response promoted 
by MDMA, but reversed the oxidative stress effects to mitochondria evoked by that same 
MDMA regimen. Authors suggested that monoamine oxidation by MAO-B may play an 
important role in the neurotoxicity induced by this amphetamine (Alves et al 2007).  
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Kelly and co-workers examined the toxicity induced by MDMA in the perinatal rat 
brain and its relation to the normal development of 5-HTT sites. They also determined 
whether early exposure to MDMA can alter brain function in future adult rats (Kelly et al 
2002). In this report, researchers evaluated perinatal development of 5-HTT sites by 
quantification of [3H]-paroxetine binding autoradiography. Time-mated female Sprague-
Dawley rats were injected s.c. with MDMA (20 mg/kg, twice daily) for four consecutive 
days, starting on gestational day 15 (E15), and neonatal male rats (from untreated dams) 
were also injected with MDMA (20 mg/kg, s.c., twice daily, for four consecutive days) on 
PND 10, 15, 20, 25, or 30. All animals groups mentioned before were sacrificed on PND 
40. Subsequently, another offspring group was injected with MDMA (20 mg/kg, s.c., twice 
daily, in four consecutive days) at PND 90 and, in this case, animals were sacrificed ten 
days after the drug treatment. The results showed no difference in the density of [3H]-
paroxetine binding sites, measured at PND 40, in brains of rats treated with MDMA from 
E15 to PND 20, when compared to controls. However, treatments with MDMA started on 
PND 25 or later resulted in significant reductions in [3H]-paroxetine binding, with 
decreases of 46% at PND 25 and 63% at PND 30, when compared to controls. These 
decreased levels were not as significant as those found in rats treated with MDMA at PND 
90, in which the density of [3H]-paroxetine binding sites decreased by 90%. These results 
suggest that the susceptibility of serotonergic terminals to MDMA-induced neurotoxicity is 
absent in the immediate perinatal period; however it is markedly increased when the 
treatment started on PND 25 and further, although not reaching the same extent as what 
is found in the adult rat brain (Kelly et al 2002). In another paper, the lack of sensitivity of 
perinatal rats to the neurotoxic effects of MDMA was also reported. MDMA (20 mg/kg, 
s.c.) was given to pregnant female Wistar rats from E6 to E20, and the rat pups were 
sacrificed at PND 15 (Aguirre et al 1998b). Other group of rats received a single dose of 
MDMA (20 mg/kg, s.c.) at PND 14, 21, 28, and 35, meanwhile adult (3-month-old) rats 
received the same regimen, and both groups were sacrificed seven days after MDMA 
treatment. The researchers observed that MDMA did not alter the density of [3H]-
paroxetine binding sites when MDMA was administered repeatedly during gestation, or as 
a single dose at postnatal ages prior to PND 28. But, when MDMA was administered at 
PND 35, 5-HTT density was significantly decreased in frontal cortex, seven days after the 
treatment. When exposure to MDMA occurred during the gestation period or at PND 14 
and 21, it did not cause any significant reduction in 5-HT and 5-HIAA levels. However, at 
PND 28 MDMA induced a significant decrease in 5-HT and 5-HIAA in the hippocampus, 
seven days after the administration. Also, at PND 35, MDMA-induced long-term reduction 
of 5-HT and 5-HIAA levels in several brain areas. The reported data indicated that MDMA 
exposure during gestational periods or during early postnatal ages did not produce 
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neurotoxicity to the serotonergic system. Moreover authors concluded that the onset of 
susceptibility to this drug is placed between PND 28 and PND 35, in this animal model 
exposed to this MDMA regimen (Aguirre et al 1998b).  
Furthermore, other studies reported that exposure to MDMA during the adolescent 
period results in long-term reductions in 5-HT levels, as well as decreases in its major 
metabolite, 5-HIAA, and reduced 5-HTT binding sites (Bull et al 2003, Bull et al 2004, 
Morley-Fletcher et al 2002, Piper et al 2005, Piper & Meyer 2004). A dose of MDMA (5 
mg/kg, i.p.) was given hourly for 4 h on two consecutive days, to young Wistar rats at PND 
28, and the involvement of the 5-HT2A receptor in the long-term anxiogenic effect was 
evaluated (Bull et al 2004). On PND 84, the rats pre-treated with MDMA showed a 27% 
decrease on social interaction, when compared to controls. Sixty days after the last 
MDMA injection, corresponding to PND 92, researchers observed significant reductions in 
hippocampal 5-HT and 5-HIAA concentrations, and 5-HT levels were also depleted in the 
frontal cortex and in the striatum. Moreover, the changes in anxiety-related behaviour was 
also examined as a possible result of modifications in the 5-HT2A receptor function, by 
assessing the behavioural response evoked by the 5-HT2A receptor agonist, 1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI), to MDMA (5 mg/kg exposure was 
followed by 1 mg/kg i.p. of DOI on PND 86). The results showed that the 5-HT and 5-HIAA 
depletions and the anxiogenic effect, after the repeated MDMA treatment, were 
accompanied by an attenuation of the anxiogenic response to DOI. Therefore the short-
term exposure to MDMA might cause a long-lasting reduction in specific 5-HT2A receptor 
mediated behaviour (Bull et al 2004). In fact, serotonergic neurotoxicity accompanied by 
an increased anxiety in the social interaction test has been reported by other authors in 
rats, 20 to 29 days after MDMA exposure (Bull et al 2003, Fone et al 2002). Other studies 
reported that intermittent MDMA administration throughout adolescence in rats can elicit 
tolerance to temperature dysregulation and 5-HT syndrome responses to the drug, and 
also produce later changes in performance of working memory and anxiety tests (Piper et 
al 2005, Piper & Meyer 2004). A study conducted by Piper and Meyer used adolescent 
rats that received MDMA (10 mg/kg, s.c.), given twice daily with an interdose interval of 4 
h, starting on PND 35 to PND 60 (Piper & Meyer 2004). Researchers observed that the 
repeated MDMA treatment led to an anorectic effect in rats, and at PND 65, rats showed 
impairments in non-spatial working memory and decreased anxiety-like behaviour. The 
results suggest that MDMA exposure during adolescence can alter subsequent cognitive 
and affective function in the absence of severe damage to the serotonergic system, since 
only mild decreases were found in 5-HT binding at PND 70 (Piper & Meyer 2004). 
Administration of MDMA also showed the ability to produce deficits in working memory 
and promote anxiety-related responses in adult rats (Gurtman et al 2002, Mechan et al 
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2002a, Morley et al 2001). Exposure to MDMA (5, 10, or 20 mg/kg, s.c., twice daily) also 
promoted changes in the learning and memory ability, as rats exposed during the period 
PND 11 to 20 revealed impairments in the sequential learning on PND 59 to 68, spatial 
learning and memory on PND 73 to 82, although rats exposed on the period PND 1-10 
presented no significant changes in the adulthood (Broening et al 2001).  
The differences in the administration scheme strongly influence the effects observed 
after MDMA exposure during adolescence. A study examined in adolescent rats the 
influence of intermittent administration of MDMA (10 mg/kg x 2, s.c., every fifth day from 
PND 35 to 60, with each dose separated by 4 h) on their behavioural, physiological, and 
neurochemical responses to a further, at PND 67, MDMA binge (5 or 10 mg/kg x 4, hourly 
for 4 h) rechallenge or a 5-HT1A receptor agonist challenge [a single dose of 0.1 or 0.5 
mg/kg of 8-hydroxy-2-(di-n-propylamino)tetralin] (Piper et al 2006). The intermittent 
exposure to MDMA during adolescence attenuated or even prevented some physiological 
behaviours and neurotoxic responses to the MDMA binge exposure at PND 67. The 
hyperthermic effects were attenuated and the locomotor hypoactivity was blocked, which 
was also accompanied by ablation of 5-HT neurotoxicity. MDMA-treated animals also 
showed an attenuation of 5-HT syndrome response promoted by a high dose of the 5-
HT1A receptor agonist. The results suggest that chronic intermittent MDMA exposure 
during adolescence may induce 5-HT1A receptor desensitization, as well as neuroadaptive 
changes that can protect against the adverse consequences of a later high-dose MDMA 
binge rechallenge (Piper et al 2006).  
Repeated intermittent MDMA binges (3 x 5 mg/kg, i.p., given 3 h apart, every 7th day 
for four weeks) were administered to adolescent rats and mice aged seven weeks 
(Kindlundh-Högberg et al 2007). In rats and mice, the total horizontal activity was 
significantly increased after the first and third weeks of MDMA binge exposure. The 
repeated intermittent administration of MDMA to rats promoted a significant down-
regulation of 5-HTT density in the nucleus accumbens‘ shell. In contrast, in mice the same 
treatment produced a significant down-regulation of DAT in the caudate putamen and 
nucleus accumbens‘ shell, and no changes in 5-HTT density. These results showed that 
the long-term intermittent administration of MDMA to adolescent rats and mice produced 
differential regulation of 5-HTT and DAT densities (Kindlundh-Högberg et al 2007). 
Repeated and intermittent administration of MDMA (5 or 10 mg/kg, i.p. for three days) 
was given to mice at different periods of development, particularly at early (28 days old), 
middle (38 days old), or late (52 days old) adolescence and the carryover effects of this 
treatment were investigated in the adulthood (80 days old) (Morley-Fletcher et al 2002). 
The referred treatment with MDMA produced, mainly at early and middle adolescence, 
long-term increases in social interaction and environment exploratory activity, and no 
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changes in the animals‘ aggressive behaviour. MDMA administration also produced long-
term reduction in hypothalamic 5-HT levels, with a specific marked reduction on the 5-HT 
concentration in mice treated at early and middle adolescence. Moreover, a rechallenge 
with MDMA (5 mg/kg, i.p.) at adulthood, after a previous exposure to MDMA during 
adolescence, induced hyperactivity in all groups, and increased hypothalamic levels of 5-
HT and reduced hypothalamic levels of 5-HIAA in all groups. These results suggest that 
the long-lasting behavioural and neurotoxic effects promoted by MDMA are dependent on 
the developmental stage at exposure to the drug (Morley-Fletcher et al 2002).  
A recent study examined the effects of repeated administration of MDMA (5 or 10 
mg/kg, i.p., once daily for four days) to rats during late adolescence (PND 38 to 41) on 
place conditioning, anxiety behaviour, and monoamine levels (Cox et al 2014). The 
treatment with 5 mg/kg of MDMA had no effect on any of the studied parameters. 
However, the 10 mg/kg MDMA treatment during adolescence caused place aversion one 
day after the last exposure to the drug, avoidant behaviours in the light-dark box, and also 
increased anxiety-like behaviours in the open field five days after cessation of MDMA. On 
the other hand, the same dose of 10 mg/kg produced no changes in monoamine levels in 
the hippocampus, decreased 5-HT levels in the dorsal raphe, and increased 5-HT and 5-
HIAA in the amygdala, five days after the last MDMA administration. These data imply that 
the production of anxiety-like behaviours is related with a more complex mechanism 
associated with regionally-distinct dysregulation of the 5-HT system. In addition, data also 
suggest that more studies are necessary to assess the mechanism that leads to this 
regionally-distinct neuroplastic changes in the monoamine system that are accompanied 
with altered behaviour (Cox et al 2014). 
A recent study was performed in rats to evaluate the effects of MDMA on 5-HTT 
densities in the frontal cortex and midbrain using single photon emission computed 
tomography (SPECT) with the 5-HTT ligand, 123I-labelled 2b-carbomethoxy-3b-(4-
iodophenyl) tropane ([123I]-β-CIT) (Klomp et al 2012). Authors aimed to access whether 
MDMA effects in 5-HTT densities were dependent on the age of first exposure. Therefore, 
they administered MDMA (10 mg/kg, s.c., twice daily for four days) to adolescent rats at 
PND 27 and to adult rats at PND 63 (+/- five days). The 5-HTT densities were evaluated 
seven days after the last MDMA treatment, at PND 38 in early-exposed (adolescent) rats 
and at PND 74 (+/- five days) in late-exposed (adult) rats. This MDMA treatment produced 
significant reductions in 5-HTT binding in several brain regions, which were less 
pronounced in adolescent rats (ranging from 20% to 69%) when compared to adult rats 
(ranging from 35% to 75%). The effect of age and treatment was observed in the frontal 
cortex of rats and not in the midbrain (probably due to an early maturation of the midbrain 
in rats). The degree of 5-HTT loss in adolescent rats (35%) was less extensive when 
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compared to adult rats (49%) after MDMA treatment, presumably because 5-HTT 
increases with the increasing age ([123I]-β-CIT binding ratios in the prefrontal cortex of 
control adult rats were 21% higher when compared to adolescent control rats). 
Researchers concluded that the differences on MDMA effects on the developing and 
mature brain might be due to differential maturational stages of the 5-HT projections at 
age of first exposure (Klomp et al 2012).  
In order to assess the importance of MDMA chirality in its behavioural effects, 
researchers treated adolescent (32 days old) rats with 5 or 10 mg/kg of RS-MDMA or with 
5 mg/kg of each one of its enantiomers, R- and S-MDMA, during two treatment stages 
(stage one: days 1 to 10; stage two: days 15, 17, 19, s.c., once per day. All the animals 
were also rechallenged with 5 mg/kg of S-MDMA on day 31 and with 10 mg/kg of RS-
MDMA on day 33 (Von Ameln & Ameln‐Mayerhofer 2010). The treatment with R-MDMA 
failed to produce hyperactivating effects, but instead decreased the locomotor behaviour. 
On the other hand, RS-MDMA or S-MDMA generated a massive hyperlocomotion and led 
to the development of behavioural sensitization. When R- and S-MDMA were 
administered together, researchers observed an increasing in hyperactivity and 
behavioural sensitization induced by S-MDMA, and the animals pre-treated with R-MDMA 
showed a sensitized response after a rechallenge with RS-MDMA in adulthood. Taken 
together, these findings suggest that both MDMA enantiomers can induce behavioural 
changes after repeated administration during adolescence, and that the sensitization 
development is more pronounced with S- and RS-MDMA (Von Ameln & Ameln‐
Mayerhofer 2010). 
Altogether, these studies may suggest that young animals are more resistant to 
MDMA immediate neurological damage, although long-term effects are still scarcely 
investigated. Furthermore, adolescent animals are vulnerable to MDMA neurotoxicity and 
the use of this amphetamine can severely influence their normal neurotransmitter 
functions, and consequently induce changes in behaviour and neurotoxicity markers. At 
this point, mainly the serotoninergic function has been deeply addressed, meaning that 
further study on MDMA-induced neurotoxicity is needed. 
Like other amphetamines, METH is also widely used by adolescents, and therefore is 
extremely important to understand its neurotoxic potential during this developmental 
period. METH administration might result in neurotoxicity, which can be characterized by 
depletion of DA, 5-HT, along with an increase in the expression of glial fibrillary acidic 
protein (GFAP). Moreover, neurotoxicity seems to be facilitated by a hyperthermic 
response (Cappon et al 1997). A single METH dose (10 mg/kg, s.c.) was given to 
developing rats at PND 20, 40, or 60 at ambient temperatures of 22ºC or 30ºC. The drug 
administration to PND 60 rats at 22ºC induced animal hyperthermia and resulted in a 47% 
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decrease of neostriatal DA, and 49% increase in the GFAP content, while administration 
to PND 40 rats at the same ambient temperature failed to induce a hyperthermic response 
and no changes in DA or GFAP were reported. Interestingly, when administered to PND 
40 rats at an ambient temperature of 30ºC, METH induced hyperthermia, and resulted in a 
54% reduction of neostriatal DA and a 70% increase in GFAP. Moreover, the METH 
administration at PND 20 did not cause DA depletion or increases in GFAP, at either 
ambient temperature. These data showed that hyperthermia is necessary to develop 
neurotoxicity at PND 40, while at PND 20 the rats are resistant to the neurotoxic effects 
induced by METH. Altogether, these data suggest that the rat neostriatal susceptibility to 
this drug may start at approximately PND 40 and the younger animals (20-day-old) are 
less susceptible to the neurotoxic effects of METH (Cappon et al 1997). 
Another study performed in rats examined the response of the monoaminergic 
system in adolescent (PND 40) and adult (PND 90) animals when subjected to a high 
dose regimen of METH (10 mg/kg, s.c., four injections, 2 h apart) (Kokoshka et al 2000). 
This treatment did not evoke death in younger rats, but led to a 20% mortality rate within 
the older group at PND 90. The treatment with METH produced long-term (seven days 
after the treatment) decreases of 33-53% in DAT activity, tyrosine hydroxylase (TH) 
activity, and DAT ligand binding in the striatum of PND 90 rats when compared to control 
rats, although these deficits were absent in PND 40 animals. In fact, 1 h after the 
treatment, DAT activity was already decreased at PND 90. In contrast, in PND 40 only 
showed a transient decrease in striatal DAT activity at 1 h, which returned to the control 
levels at seven days. Moreover, to examine the effects of METH to the serotonergic 
systems, researchers also measured the long-term (seven days) and acute (1 h) 
responses induced by this drug to TPH activity, and observed reduced striatal TPH activity 
in both PND 40 and 90 animals. There was also an age-dependent difference in the 
concentration of METH in the striatum and plasma 1 h after the drug administrations, with 
PND 90 having the double concentration of METH when compared to PND 40 rats. These 
data clearly showed an age-dependent difference in the long-term monoaminergic 
responses to METH exposure, which might also be related to the age differences in 
METH pharmacokinetics. However, in the acute settings, serotoninergic system seems 
equally sensitive in both populations (Kokoshka et al 2000).  
In mice, METH also induces age-related different responses in terms of dopaminergic 
neurotoxicity. The neurotoxic regimen of METH (4 x 10 mg/kg, s.c., every 2 h) produced 
minimal and non-persistent depletion of DA and its metabolites in 1-month-old mice, while 
mice with 12 months of age suffered large and persistent depletions of DA (87%), DOPAC 
(71%), and homovanillic acid (HVA) (94%) in the striatum (Miller et al 2000). This METH 
regimen was also minimally effective in inducing elevations of GFAP in 1-month-old mice, 
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when compared to the large elevations in striatal GFAP in mice of 2, 5, 12 or 23 months of 
age. Moreover, with increasing dosages of METH (4 x 20, 40 or 80 mg/kg, s.c., every 2 h) 
the response of GFAP increased by 100% over control in one-month-old mice, but it still 
remained extremely below the levels of increase reported in mice with 12 and 23 months 
of age (300-400% over control). These results also suggest that younger animals are less 
susceptible to the neurotoxic damage induced by METH, and this neurotoxicity might be 
dependent on the maturity of the striatal DA systems (Miller et al 2000).  
In another study, METH (0, 5, 10, 20, and 40 mg/kg, i.p., single dose) was 
administered to rats with 1, 6, or 12 months. The administration of 40 mg/kg METH 
resulted on 100% mortality in 12-month-old animals (Imam & Ali 2001). In the striatum of 
1-month-old rats after the 5 mg/kg METH dose there was no formation of 3-nitrotyrosine, 
indicating no formation of peroxynitrite, and no dopaminergic alterations. However, at this 
age the administration of 10, 20, and 40 mg/kg METH produced a significant dose-
dependent increase in 3-nitrotyrosine and dose-dependent depletions of DA and its 
metabolites, DOPAC and HVA, when compared to the paired control group. In the 6-
month-old rats, all METH doses (5, 10, 20, or 40 mg/kg, i.p.) produced a significant 
increase in 3-nitrotyrosine formation in a dose-dependent manner, and the levels were 
also higher when compared to those of 1-month-old rats. In this age, rats also reported 
dose-dependent depletions in DA and its metabolites, in all dosages used. Moreover, a 
single injection of METH (5, 10 or 20 mg/kg, i.p.) also resulted in a significant dose-
dependent formation of striatal 3-nitrotyrosine on 12-month-old rats, which was 
significantly higher when compared to the other two younger groups tested. In this group 
also occurred a significant dose-dependent depletion of DA, DOPAC, and HVA levels, and 
dopaminergic neurotoxicity was more pronounced when comparing to the 1-month-old or 
6-month-old METH-treated rats. Moreover, an age-dependent increase in the 
hyperthermia was also reported after METH administration. Hence, these results suggest, 
once again, that aging increases the susceptibility of animals to neurotoxic doses of 
METH (Imam & Ali 2001). 
A study performed in rats used a biweekly treatment with METH (7.5 mg/kg on 
consecutive days, s.c., for six weeks) that started in adolescence (PND 40) and a binge 
treatment (4 x 7.5 mg/kg, 2 h apart, s.c.) in adulthood (PND 90) (Mcfadden et al 2011). 
The drug treatment during adolescence had no effects, in contrast to the binge treatment 
at PND 90 that caused acute and persistent deficits in VMAT2 function. However, the 
biweekly treatment during adolescence prevented the acute and persistent deficits in 
VMAT2 function and the acute hyperthermic response caused by the subsequent METH 
rechallenge in adulthood. Nevertheless, when the rechallenge was administered at a 
higher ambient temperature, the hyperthermia was maintained and the referred protection 
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produced by the biweekly treatment during adolescence was abolished. These results 
demonstrate that the administration of METH during development prevents against the 
hyperthermia and dopaminergic toxicity promoted by a later exposure in the adulthood 
(Mcfadden et al 2011).   
Another study tested the dose-response to successive ten-day intervals of METH 
exposure in rats within the periods PND 21 to PND 30, PND 31 to PND 40, PND 41 to 
PND 50, or PND 51 to PND 60 (Vorhees et al 2005). Several METH doses were tested in 
each group of animals. Some METH regimens failed to produce changes in the spatial 
learning/reference memory and sequential learning, namely on PND 21-30 (2.5, 5, or 10 
mg/kg/dose x 4 dose/day, s.c.), PND 31-40 (1.25, 2.5, 5 or 7.5 mg/kg/dose x 4 dose/day, 
s.c.), or PND 51-60 (1.25, 2.5, 3.75 or 5 mg/kg/dose x 4 dose/day, s.c.). But impairments 
in spatial learning/reference memory and sequential learning were seen after treatment 
with the highest dose (6.25 mg/kg/dose, s.c.) on PND 41-50 (1.25, 2.5, 5 or 6.25 
mg/kg/dose x 4 dose/day, s.c.). The effects observed at PND 41-50, which is in the 
adolescent stage of brain development in rodents, suggests that, at this age, there is a 
superior susceptibility of rats to cognitive deficits induced by METH when compared to 
juvenile (PND 21-30, PND 31-40) or adult rats (PND 51-60) (Vorhees et al 2005).  
A study in adolescent mice (28-42 days old) with exposure to a repeated neurotoxic 
regimen of METH (24 mg/kg, i.p., once daily, for 14 days) was conducted to ascertain if 
METH exposure promoted changes in hippocampal plasticity or short-term memory (North 
et al 2013). Researchers observed that after 14 days of METH exposure there were no 
deleterious consequences on short-term memory or hippocampal neurotransmission. 
However, after a period of 21 days of drug abstinence they found deficits in spatial 
memory and decreases in hippocampal plasticity. Authors concluded that the deleterious 
consequences on short-term memory and hippocampal neurotransmission induced by a 
neurotoxic regimen of METH may manifest and persist after an abstinence period (North 
et al 2013).  
To sum up, the developing animals appear to be protected, at least in part, against 
METH neurotoxicity, hence the susceptibility of animals to the neurotoxic effects 
increased with the animal age. Besides, PND 40 might be the halfway age between the 
developmental and adult response patterns to this drug.  
 
1.6.3. Humans 
 
Studying the long-term consequences of amphetamines use by humans is extremely 
important, for an adequate awareness of the neurotoxic effects in drug users. However, it 
is difficult to extrapolate the results obtained in animal experimentation to humans, being 
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increasing relevant to confirm the ATS neurotoxicity demonstrated in laboratory animals 
with studies conducted in human subjects. Importantly, studies performed in young adults 
are necessary to assess the effects of amphetamines at this developmental stage, since 
these psychoactive drugs are extensively consumed by young people. Also, the 
assessment of the neurotoxicity in previous consumers in adolescence can warrant 
important data. 
As previously mentioned, AMPH is not only a recreational drug, since it is also used 
for ADHD therapy in children and adolescents. For that reason, researchers have shown 
concerns due to the possible neurotoxic effects of this drug. Unfortunately, the adolescent 
human population is understudied. Studies with human adolescents have some ethical 
barriers, due to their age. Thus, they are frequently not enrolled in studies to evaluate the 
drug abuse consequences. Several investigators evaluate the later consequences of 
possible exposure to the drugs during adolescence in people with more than 18 years old 
(King et al 2010). Below are reviewed the few studies conducted mostly in young adults to 
evaluated the neurotoxic consequences of the drug. 
Reske and co-workers performed a study in non-dependent stimulant users, with 
ages between 18 and 25 years that used AMPH and methylphenidate at least for the past 
six months, to assess the behaviour and brain functioning under the occasional use of 
these drugs. It was observed that an increased use of AMPH and methylphenidate was 
associated with strong verbal memory and learning deficits. Also, the learning and 
memory problems were present in individuals with a minimal use of stimulants, leading to 
possible pre-existing neurocognitive impairments in the studied population. Even so, they 
concluded that the prescription of AMPH and methylphenidate may lead to an 
intensification of these deficits (Reske et al 2010).    
A paper reported the AMPH effects on motor and verbal skills, memory, and spatial 
attention task in 18 healthy volunteers (with an average age of 25.4 ± 6.51 years) with the 
help of functional magnetic resonance imaging (fMRI) (Willson et al 2004). In that study, a 
single oral dose of 25 mg d-AMPH caused decreases in brain activity in several regions 
during cognitive tasks. These effects may be linked to the behavioural changes observed 
after the AMPH administration, and are possibly mediated by alterations in dopaminergic 
activation (Willson et al 2004). 
―Poly-drug-but-no-ecstasy users‖ (extensive use of AMPH and/or cocaine who 
consumed AMPH, on average, for 78 times), with ages between 18 and 37 years, showed 
high impairment in memory performance, which can be related to different mechanisms of 
the drugs, due to the different affinities to the neurotransmitter systems by these drugs 
(Jager et al 2007). 
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―Ecstasy‖ is also widely used by young humans, being extremely important to study 
the neurotoxic effects in MDMA users. A fMRI study on 33 heavy MDMA users (mean use 
of 322 pills) with a mean age of 23 ± 3.8 years, evaluated the effects of ―ecstasy‖ on 
working memory, attention, and associative memory. The results showed that the use of 
this drug had no effects on working memory and attention, but was associated with 
reduced memory performance. Memory performance is apparently more affected by 
AMPH than MDMA in humans (Jager et al 2007). Several studies reported a decreased 
density in 5-HT neurons, with reduced 5-HTT binding sites in young adult MDMA users 
(McCann et al 1998, McCann et al 2005, McCann et al 2008). Brain 5-HT density is 
related with memory performance, suggesting that the observed deficits in 5-HTT will be 
related with the deficits in memory seen in humans with an history of MDMA abuse 
(McCann et al 2008). An investigation conducted in 49 chronic ―ecstasy‖ users (mean four 
years, typically one to two tablets bi-monthly), with an average age of 25.9 ± 0.8 years, 
reported a significant decrease in 5-HTT binding in cerebral cortex (19-46% loss of 5-
HTT), and hippocampus (21% loss of 5-HTT) (Kish et al 2010). Those effects were related 
with the years of drug use. Moreover, the MDMA users reported subnormal mood and 
deficits in some attention tests, executive function and memory, and the memory deficits 
were correlated with the decreased 5-HTT binding sites (Kish et al 2010), which 
corroborates the previous study. In another study performed in MDMA users (with an 
average age of 26.23 ± 1.99 years and an average MDMA use of 4.52 ± 0.71 years), it 
was observed that this drug decreased the levels of 5-HT metabolite, 5-HIAA, in the 
cerebrospinal fluid. Moreover, it was stated that the brain 5-HT injury might be related with 
cognitive deficits, since the MDMA users revealed performance deficits on several tasks, 
namely sustained attention task requiring arithmetic calculations, a task that required 
complex attention and incidental learning, a task requiring short-term memory, and a task 
of semantic recognition and verbal reasoning (McCann et al 1999). Other studies also 
reported possible 5-HT neurotoxicity, which was related with evidences of cortical hyper-
excitability and chronic alterations in cortical 5-HT signalling in MDMA users, aged 
between 18 to 35 years old (Bauernfeind et al 2011, Di Iorio et al 2012).  
A recent study was performed in adolescents (14-18 years) and young adults (18-36 
years) to evaluate the effects of MDMA on brain 5-HTT densities in the frontal cortex and 
midbrain using SPECT and the 5-HTT ligand, [123I]-β-CIT (Klomp et al 2012). The MDMA 
users were stratified in two different groups: group one with ages between 14-18 years, 
representing the early-exposed group (developing brain), and group two with ages 
between 18-36 years, representing the late-exposed users (mature brain). On average, 
five years after the first exposure, researchers reported that early age of first exposure 
accounted a notable 79% of midbrain 5-HTT density variability in the developing human 
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brain, in contrast to 0.3% variability in late-exposed users. No relationship between age at 
first MDMA use and 5-HTT binding was observed in the frontal cortex. It was concluded 
that the differential effects of MDMA on the developing and mature brain might be due to 
differential maturational stages of the 5-HT projections at age of first exposure (Klomp et 
al 2012). 
A study conducted with 31 polydrug users that consume MDMA (average age of 21.7 
± 3.3 years old and abstinent from MDMA at least three weeks before starting the study) 
versus 29 non-MDMA users with history of abuse of other substances (average age of 
24.3 ± 3.5 years old) compared their brain grey and white matter concentration. The 
researchers observed that MDMA users had decreased grey matter concentration in 
several brain regions (neocortical, bilateral cerebellum, and midline brainstem) (Cowan et 
al 2003). With the aim of assessing the sustained effects of ―ecstasy‖ on the brain, 
researchers performed a study in abstinent novel ―ecstasy‖ users (low-dose MDMA users) 
with a combination of neuroimaging techniques. The researchers used young adults with 
a mean age of 21.7 ± 3.0 years that consumed, on average, six tablets in 20.3 ± 23.8 
weeks. They observed that novel users, even in low doses of the drug, showed signs of 
damage in the brain, such as vasoconstriction and axonal damage (de Win et al 2008). 
Flavel and co-workers performed a study in MDMA abstinent users, with an average 
age of 22 ± 3 years old, to assess the late effects of this stimulant on human tremor during 
rest and movement. The MDMA users surprisingly presented an abnormal large tremor 
during movement, since the subjects had a minimal to moderate lifetime use of MDMA 
(subjects that used MDMA on less than 20 occasions) and had been abstinent for an 
average of three months. These data suggests no associations with an acute mechanism 
of action of the drug. The authors stated that these abnormalities may account for a 
possible risk for movement disorders in MDMA users (Flavel et al 2012). The same group 
reported abnormal substancia nigra morphology in abstinent illicit stimulant (AMPH, 
MDMA, METH and cocaine) users with an average age of 31 ± 9 years. These deficits in 
nigro-striatal system raised some concerns, giving the high risk for a later development of 
Parkinson‘s disease (Todd et al 2013). 
The evaluation of former (even abstinent) MDMA use during adolescence 
demonstrates that the use of this drug may affect the neurotransmitter function and 
reduce memory performance. Moreover, researchers state that the distinct maturational 
brain stages may have an important role in the long-term consequences of ―ecstasy‖ use.   
Like other amphetamines, METH is also widely abused by humans and it‘s extremely 
important to assess the neurotoxic actions of METH in humans‘ brain. McKetin and co-
workers presented a paper with 309 METH users with ages ranging from 16 to 60 years-
old, being the median age of first use of the drug at 17 years old. They observed that 23% 
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of the participants had experienced clinically significant suspiciousness and 30% of the 
participants screened positive for psychosis in that year. That leads to the thought that 
chronic use of METH might be associated with the development of paranoid psychosis 
(McKetin et al 2006).  
A study involving 54 adolescent METH users and 74 control subjects, with ages 
ranging from 12 to 23 years old, assessed the neuropsychological performance of these 
adolescents after exposure to METH (an average use of 0.58 ± 0.08 g per day in males 
and 1.02 ± 0.22 g per day in females). All subjects were submitted to several 
neuropsychological tests and the METH users presented impairments in memory and 
executive function. Moreover, these impairments appear to be attenuated by a prolonged 
abstinence to the drug. Researchers concluded that the use of METH is associated with 
cognitive deficits (King et al 2010). 
A study with 34 METH-dependent adults with an average age of 33.1 ± 8.9 years 
(population generally used the drug for ten years, in a frequency superior to five times per 
week, and abstinent for 18 days) and 31 healthy non-METH user subjects with an average 
age of 35.7 ± 8.4 years, measured the grey matter volumes in the both groups. METH 
users showed an age-dependent loss of cortical grey matter in frontal, occipital, temporal, 
and the insular lobes when compared to control subjects, and smaller grey matter 
volumes in several brain subregions. The authors concluded that METH users increased 
their grey matter loss with age, raising the possibility of accelerated decline in mental 
function (Nakama et al 2011). As reported for MDMA, METH abusers also presented grey 
matter deficits, a marker of neurotoxicity (Schwartz et al 2010, Thompson et al 2004). 
Researchers pointed that METH users, which used the drug for an average of 10.5 years 
starting at their mid-twenties, had 7.8% smaller hippocampal volumes than control 
subjects and that data was associated with impaired memory performance. They also 
reported a significant white matter hypertrophy of 7.0%, accompanied with damage in the 
medial temporal lobe and in the cingulated-limbic cortex in METH users. Altogether, these 
indications of cerebral deterioration caused by chronic METH use can lead to impairments 
of memory performance (Thompson et al 2004). Other authors reported that the use of 
drugs in a juvenile age (subjects that initiated the drug use before 21 years old) was 
related with smaller intracranial volume (Schwartz et al 2010). 
Regarding METH use in adolescence, studies show evidences of long-term 
neurotoxicity, such as, grey matter loss, development of paranoid psychosis, cognitive 
deficits and impaired memory performance.  
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2. AIMS 
 
―Ecstasy‖ neurotoxic properties have been studied in laboratory animals and humans. 
Given the fact that MDMA is a widespread illicit recreational drug frequently used by many 
teenagers and young adults, there is a need to understand the consequences of exposure 
to this drug during adolescence. In particular, the adolescent period is frequently 
neglected by investigators, as well as the potential differences among different aged 
groups. Specifically, it is extremely important to clarify the actions of MDMA to the 
adolescent developing brain. Moreover, in this context, the cerebellum was never 
approached. 
The main aim of this dissertation was to assess the acute toxicity and oxidative stress 
of this drug in an adolescent rat model (postnatal day 40) promoted by a binge 
administration scheme comparable to humans. MDMA abusers frequently intake several 
doses of ―ecstasy‖ on the same session, using the binge scheme of administration. The 
acute toxicity of this drug to the adolescent rat brain was evaluated in four different brain 
areas (cerebellum, hippocampus, cortex and striatum) and in three peripheral organs 
(liver, heart and kidneys) 24 h after the MDMA administration. Another aim of this thesis 
was to evaluate the long-term effect of age in the neurotoxicity of MDMA using adolescent 
(postnatal day 40) and aged rats (18 to 22 months old). In particular, long-term effects in 
the cerebellum were evaluated in both adolescent and aged rats, seven days after the 
MDMA administration, since the effects in this brain area are scarcely studied, and little is 
known about the susceptibility of different aged groups. To achieve the referred aims, 
several techniques were performed being the redox status, energetic content, protein-
bound quinones formation and protein carbonylation evaluated. 
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3. MATERIALS AND METHODS 
 
3.1. Materials 
 
Dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic acid (EDTA), Folin–Ciocalteu 
reagent, perchloric acid, sodium hydroxide (NaOH), cupper (II) sulphate (CuSO4), sodium 
carbonate (Na2CO3), potassium bicarbonate (KHCO3), magnesium chloride (MgCl2), 
magnesium sulphate (MgSO4), potassium dihydrogen phosphate (KH2PO4) and disodium 
phosphate (Na2HPO4) were purchased from Merck (Darmstadt, Germany). Sodium 
phosphate monobasic (NaHPO4) was purchased from Panreac (Barcelona, Spain), 
potassium sodium tartrate from Fluka (Buchs SG, Switzerland), phosphate buffered saline 
solution (PBS) from Biochrom (Berlin, Germany), 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), methanol, xylene from Fisher Scientific (Loughborough, 
UK), sodium chloride (NaCl), and sodium dodecyl sulphate (SDS) from VWR (Leuven, 
Belgium). EMLA® Lidocaine 25 mg/g + Prilocaine 25 mg/g was purchased from 
AstraZeneca (London, UK). Isoflurane (Isoflo® 100% p/p) was obtained from Abbott 
Animal Health (North Chicago, IL, USA). The fluorescent peptide substrates for caspase-3 
(Ac-DMQD-AMC), the peptide substrate for caspase-8 (Ac-IETD-AMC), and for the 
peptide substrate for caspase-9 (Ac-LEHD-AMC) were obtained from Peptanova 
(Sandhausen, Germany). ABX Pentra reagents were purchased from HORIBA (Kyoto, 
Japan). Bio-Rad DC protein assay kit and the Clarity Western ECL Substrate were 
purchased from Bio-Rad Laboratories (Hercules, CA, USA). Horseradish peroxidase 
(HRP) conjugated anti-rabbit antibody, and 0.45 µm Amersham Protran nitrocellulose 
blotting membrane was purchased from GE Healthcare Bio-Sciences (Pittsburgh, PA, 
USA). Dinitropenhyl-KLH rabbit IgG antibody was purchased from Invitrogen/Life 
Technologies (Grand Island, NY, USA). Eosin 1% aqueous was obtained from Biostain 
(Traralgon, Australia), Harris hematoxylin was from Harris Surgipath (Richmond, IL, USA) 
and Histofluid from Marienfeld (Lauda-Königshofen, Germany). MDMA (HCl salt) was 
extracted and purified from high purity MDMA tablets, which were provided by the 
Portuguese Criminal Police Department. The extracted salt was fully characterized by 
nuclear magnetic resonance and mass spectrometry (Capela et al 2007a, Capela et al 
2007b). All the other reagents used were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 
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3.2. Animals 
 
All procedures were carried out to provide an appropriate animal care, minimizing 
their suffering. Housing and experimental treatment of the animals were in accordance 
with the guidelines defined by the European Council Directive (2010/63/EU). Moreover, 
the experiments were performed with the approval of the Portuguese National Authority 
for Animal Health (General Directory of Veterinary Medicine) and the Ethical Committee of 
the Faculty of Pharmacy, University of Porto (opinion nº 17/03/2014). 
In this study, two different populations were used, adolescent and aged male Wistar 
rats born in the Institute for Biomedical Sciences Abel Salazar, University of Porto 
(ICBAS-UP) vivarium. The animals were maintained under a controlled ambient 
(temperature 22.0 ± 2.0ºC, 40% humidity, 12 h light/dark cycles) and given ad libitum 
access to food and water. In the adolescent population group, 24 rats at PND 40, 
weighing an average 136 g were used. In the aged population, 11 rats with ages between 
18 to 22 months and an average body weight of 505 g were used. 
 
 
3.3. Experimental protocol 
 
Two experiments were conducted in order to assess the susceptibility of different 
populations of rats to MDMA, one adolescent and the other aged, in an administration 
schedule that mimics human MDMA-pattern of use (binge use) and uses realistic human 
doses (Capela et al 2009, Goni-Allo et al 2008). Two different MDMA solutions in sterile 
NaCl 0.9% were prepared: 2.5 mg/mL for the adolescent rats, and 5.0 mg/mL for the aged 
rats. Three days before both experiments, animals were trichotomised in the lumbar 
region and anesthetized locally with a local anaesthetic (EMLA ® Lidocaine 25 mg/g + 
Prilocaine 25 mg/g). Each animal was also anesthetized with isoflurane before inserting a 
s.c. temperature transponder (BioMedic Data Systems Inc., Seaford, DE), in the lumbar 
region, as to allow core body temperature measurement (Alves et al 2007). In the days 
prior to MDMA administration, they were housed in groups allowing socialization, except 
for the aged rats, which given their size were individually caged to maintain animal 
comfort. In the day of the experiment, animals were caged individually. 
In experiment one, adolescent animals were exposed to an MDMA binge regimen (3 
x 5 mg/kg) and sacrificed 24 h after the beginning of treatment. Regarding experiment 
two, two different populations were used: adolescent and aged animals, which also 
received via i.p. route the MDMA binge administration (3 x 5 mg/kg and 2 x 5 mg/kg, 
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respectively), but were sacrificed seven days after exposure to the drug. Four different 
brain areas (cerebellum, hippocampus, cortex and striatum), and three peripheral organs, 
liver, heart and kidneys were collected in the first experiment. In experiment two only the 
cerebellum brain area was studied. 
 
3.3.1. Experiment 1 
 
In experiment one, 14 adolescent male Wistar rats were divided in two groups: 
control (n=7) and MDMA-treated (n=7). The MDMA-treated group received three doses of 
5 mg/kg MDMA, i.p., every 2 h, for a total dose of 15 mg/kg. To control animals was given 
NaCl 0.9% (saline solution) in the same schedule and equivalent injection volume of 
MDMA-treated conditions. During administration, the temperature of each animal was 
monitored and registered every 15 min for a total of 7 h. The weight of the animals, and 
their food and water intake were assessed before the first injection and at the next day, 
approximately at the same hour of the first administration. Twenty-four hours after the 
MDMA administration, animals were prepared to leave the vivarium and housed in groups 
for transportation. The adolescent rats were sacrificed, approximately, 24 h after the first 
dose administration (Figure 4). This binge dosing regimen (three doses of 5 mg/kg 
MDMA, i.p., every 2 h) used was previously described in adult ten week old Wistar rats, 
with an average weight of 300 g, to promote serotonergic neurotoxicity (Goni-Allo et al 
2008). This regimen of MDMA in adolescent Wistar rats PND 40 was proven to not 
promote serotonergic toxicity seven days after MDMA exposure, as no depletion of 5-HT 
could be seen in any of the brain areas analysed in the present study (Feio-Azevedo et al 
Submitted). Regarding the equivalence of doses to humans, the equivalence was based 
on the allometric scaling principles using the formula: dose Human (mg/kg) = dose animal 
(mg/kg) x (animal weight/human weight)1/4 (Hayes 2001). According to this correlation, the 
dose used in adolescent rats (MDMAtotal dose= 15 mg/kg of body weight) is approximately 
equivalent to 170 mg in a 50 kg adolescent human. The majority of human abusers 
usually take more than one tablet per session, normally from two to four tablets using the 
binge dosing pattern (Morgan 1998, Scholey et al 2004). The latest European Union 
report on drugs mentioned that the seized MDMA pills during 2012 had a mean range of 
57 to 102 mg with high purity (EMCDDA 2014), which means that the dose used in our 
protocol can be equivalent to the intake of two to three pills by human adolescents. 
Therefore, the present paradigm of exposure to animals can mimic the dose schedule 
used by human adolescents. 
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Figure 4 – Experiment one was conducted with 14 adolescent rats. Three doses of NaCl 0.9% or three doses 
of MDMA 5 mg/kg were administrated intraperitoneally (i.p.), every 2 h, to controls (n=7) or to MDMA-treated 
animals (n=7), respectively. MDMA total dose was 15 mg/kg. Temperature was monitored for 7 h, starting at 
the first administration. Temperature, animal weight, food and water intake were assessed before and 24 h 
after MDMA exposure. The animals were sacrificed 24 h after the administration and four different brain areas 
(cerebellum, hippocampus, cortex and striatum), and three peripheral organs (liver, heart and kidneys) were 
collected.  
 
3.3.2. Experiment 2 
 
Two different populations of male Wistar rats were used in this experiment: 10 
adolescent (PND 40) and 11 aged (18 to 22 months old) animals.  
The adolescent animals were divided in control (n=5) and MDMA-treated (n=5) 
groups. The MDMA-treated group received three doses of 5 mg/kg MDMA (i.p.), every 2 
h, (MDMAtotal dose= 15 mg/kg of body weight), the same regimen used in experiment one. 
Control animals received NaCl 0.9% (saline solution) in the same schedule and equivalent 
injection volume of MDMA-treated conditions.  
Concerning the aged population, on the day of the experiment, two groups were 
formed: control (n=5) and MDMA treated (n=6). Given the high risk of mortality due to the 
high temperature reached after the second MDMA dose, and given the fact that one 
animal dyed of extreme hyperthermia several hours following the last injection (in this 
animal the core temperature surpassed 41ºC), it was decided, to assure animal survival 
and welfare, that aged rats would not receive the third dose of MDMA. Of note, that no 
data from the deceased animal were included in the results of aged rats. Accordingly, in 
the aged population, MDMA-treated rats only received two doses of 5.0 mg/kg MDMA i.p., 
every 2 h (MDMAtotal dose= 10 mg/Kg of body weight), and two doses of saline solution were 
given to controls. According to the same allometric principles mentioned above for 
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experiment one, the total dose used in aged rats (MDMAtotal dose= 10 mg/Kg of body 
weight) is equivalent to 200 mg in a 70 Kg human. Therefore, by the same rationale 
mentioned above, the present dose given to aged animals can be equivalent to the intake 
of two to three pills and mimic the dose schedule used by humans. 
As previously said, the regimen of MDMA used in this experiment was shown not to 
promote serotonergic toxicity seven days after MDMA exposure in adolescent rats. 
However, the MDMA regimen used in aged rats (2 x 5 mg/kg, i.p., 2 h apart) was shown to 
promote serotonergic depletions in the hippocampus, but not in the cerebellum (Feio-
Azevedo et al Submitted). In both populations, the temperature of each animal was 
measured and registered for 6 to 7 h, every 15 min, starting at the first dose 
administration. For the next seven days, the temperature and weight of the animal, food 
and water intake were registered approximately at the same hour of the first injection. At 
the seventh day, animals were prepared to leave the vivarium and housed in groups for 
transportation. Both adolescent and aged rats were sacrificed seven days after the 
exposure to MDMA (Figure 5). 
 
 
 
Figure 5 – Experiment two was conducted with 10 adolescent rats and 11 aged rats. The adolescent rats 
received three doses of NaCl 0.9% (control group, n=5) or MDMA 5 mg/kg (MDMA-treated group, n=5) 
intraperitoneally (i.p.), every 2 h. MDMA total dose administered to adolescents was 15 mg/kg. The aged rats 
received two doses of NaCl 0.9% (control group, n=5) or MDMA 5 mg/kg (MDMA-treated group, n=6), i.p., 
every 2 h. MDMA total dose administered to aged rats was 10 mg/kg. Temperature was monitored for 6 to 7 h, 
starting at the first administration. Temperature, animal weight, food and water intake were assessed before 
and during the seven days following MDMA exposure. The animals were sacrificed seven days after the 
administration and the cerebellum was collected. 
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3.4. Blood and tissue collection 
 
In both experiments, animals were anesthetized and euthanized in a chamber with 
the general anaesthetic isoflurane.  Blood was, immediately, collected from the inferior 
vena cava, and decapitation followed. Blood was used to determine the levels of total 
creatine kinase (CK-R), creatine-kinase MB (CK-MB), aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT). In experiment one, immediately after the sacrifice, 
the brain was weighted and then dissected into four brain areas (cerebellum, 
hippocampus, frontal cortex and striatum). Three peripheral organs were collected (liver, 
heart and kidneys) and weighted. In experiment two, only the cerebellum was removed, 
seven days after MDMA administration, and handled as referred below for the brain areas 
of experiment one. 
The four brain areas dissected from the left side of each hemisphere were 
homogenized in perchloric acid solution 5% using a sonicator (20 seconds, continuously) 
being the tubes maintained on ice. Homogenates were then centrifuged at 13,000 rpm, for 
10 min at 4ºC, and the supernatants were collected for total glutathione (GSHt) or 
oxidized glutathione (GSSG), and adenosine 5‘-triphosphate (ATP) determination. The 
pellet was kept for posterior protein determination. The areas from the right side of the 
hemisphere were collected in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, 0.25 mM phenylmethanesulfonyl fluoride (PMSF), 
1 mM sodium fluoride (NaF), 1 mM sodium metavanadate (NaVO3), proteases inhibitor 
cocktail from Sigma, pH=8.0). The samples were also homogenized using a sonicator (20 
seconds, continuously), while tubes were maintained on ice. The resultant homogenates 
were centrifuged at 13,000 rpm, for 15 min at 4ºC, and the supernatants were separated 
to the quinoprotein and protein carbonylation assays.      
A 2 mm section of liver, heart and kidneys was collected into a 4% paraformaldehyde 
solution in PBS, and kept on ice for further treatment. Another section of liver, heart and 
kidneys was collected in complete caspase lysis buffer (25 mM HEPES, 5 mM MgCl2, 1 
mM EDTA, 0.5% Triton X-100, 1 mM PMSF and 5 mM dithiothreitol (DTT), pH=7.4) for 
caspases activity determination and was immediately stored at -80ºC. Another section 
was collected in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris, 0.25 mM PMSF, 1 mM NaF, 1 mM NaVO3, proteases inhibitor 
cocktail from Sigma, pH=8.0) and frozen at -80ºC. The samples stored in RIPA buffer 
were homogenized using a sonicator (30 seconds, continuously) while the tubes were 
maintained on ice. Homogenates were then centrifuged at 5,000 rpm, for 10 min at 4ºC, 
and the supernatant was separated to clean tubes for the quinoprotein and protein 
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carbonylation assays. The remaining of each organ was homogenized in a 0.1M KH2PO4 
solution (pH=7.4) using an Ultra-Turrax. Following homogenization, one aliquot was 
added to perchloric acid (final concentration 5%). The resultant mixture was centrifuged at 
13,000 rpm, for 10 min at 4ºC, and the supernatant was collected and separated to clean 
tubes for GSHt or GSSG, and ATP determination. The samples concerning the 
GSH/GSSG analysis were stored at -20ºC, and the samples for ATP determination were 
frozen at -80ºC. The remaining tissue homogenate was also stored at -20ºC for protein 
quantification. All these procedures were performed on ice.  
 
 
3.5. Measurement of CK-R, CK-MB, AST and ALT 
 
The blood was collected in EDTA-containing tubes and centrifuged at 920g for 10 
min, in order to separate the plasma. The plasma was frozen at -20ºC until determination 
of CK-R, CK-MB, AST and ALT. These parameters were determined using enzymatic 
assays in the apparatus ABX Pentra 400 with ABX Pentra reagents (HORIBA, Kyoto, 
Japan), according to the manufacturer‘s instructions. The determinations were performed 
by Drª Laura Pereira, at clinical analysis laboratory of the Faculty of Pharmacy University 
of Porto.    
 
 
3.6. Measurement of GSHt, GSH and GSSG 
 
The GSHt and GSSG levels were evaluated in the four brain areas and peripheral 
organs of rats in experiment one, and also in the cerebellum for experiment two, by the 
5,5‘-dithiobis(2-nitrobenzoic acid) (DTNB)-GSSG reductase recycling assay, as described 
in previous works (Capela et al 2007a, Costa et al 2007). The quantification of GSHt 
levels in the brain areas and organs was initially performed by neutralization of the sample 
homogenates and standards with 0.76 M KHCO3, followed by centrifugation for 2 min at 
13,000 rpm (4ºC). Before the measurements, the reagent solution containing 0.68 mM 
nicotinamide adenine dinucleotide phosphate (NADPH) and 3.96 mM DTNB was prepared 
in a phosphate buffer (71.5 mM NaHPO4, 71.5 mM Na2HPO4 and 0.63 mM EDTA, pH 
7.0), and was kept protected from light. In a 96-well plate (Biotek PowerWaveX plate 
reader, VT, USA), 100 µL of neutralized samples, standards or blanks, was added in 
triplicates, and mixed with 65 µL of the reagent solution. An incubation at 30ºC for 15 min 
followed. Afterwards, 40 µL of freshly reconstituted glutathione reductase solution (10 
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U/mL in phosphate buffer) was added to each well. The 5-thio-2-nitrobenzoic acid 
formation was monitored for 3 min in 10 seconds intervals, at 415 nm, and compared with 
the standard GSHt curve. Standards were made in perchloric acid solution 5%, being the 
range of concentrations used between 0.5 to 15 µM. 
To determine GSSG levels, before the neutralization 10 µL of 2-vinylpyridine was 
added to the samples homogenates, standards and blanks and mixed for 1 h, on ice, to 
block the reduced glutathione (GSH). The determination of GSSG was then performed as 
described for GSHt. The GSSG standard solutions were also made in 5% perchloric acid 
with concentrations that ranged between 0.25 and 8.00 µM. The levels of GSH were 
calculated using the next formula: GSH = GSHt – 2 x GSSG. The levels of GSHt, GSSG 
and GSH were normalized to the protein content, and the results were expressed in nmol 
of GSH or GSSG per mg of protein.  
 
 
3.7. Assessment of ATP levels 
 
ATP levels of the different brain areas, liver, heart and kidneys in experiment one, 
and of the cerebellum in experiment two were determined using a bioluminescent assay, 
based on the generation of light using the luciferin-luciferase system (Capela et al 2007a, 
Costa et al 2007). Aliquots of D-luciferin 90.9 mg/L stock reagent and luciferase from 
Photinus pyralis (firefly) (concentration of 3,000,000 U/mL) were prepared in a luciferin-
luciferase buffer [50 mM glycine, 100 mM MgSO4, 1 mM Tris-base, 0.55 mM EDTA and 
0.1% bovine serum albumin (BSA), pH=7.6] and kept, until use, at -20ºC, protected from 
light. An ATP standard curve was prepared in perchloric acid 5% solution with 
concentrations ranging from 0.625 to 10 µM. At the day of the assay, the stock solutions 
of luciferase and luciferin were mixed and maintained at room temperature. The samples 
and standards were neutralized using 0.76 M KHCO3, and then centrifuged at 13,000 rpm 
for 10 min, at 4ºC. After centrifugation, 100 µL of the samples or standards supernatants 
was added to a 96-well white microplate. Then, 100 µL of luciferin-luciferase reagent 
solution was added to each well and bioluminescence was immediately read in a 
microplate reader Biotech Synergy HT (VT, USA). The results were expressed in nmol of 
ATP per mg of protein.  
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3.8. Determination of protein-bound quinones (quinoproteins) 
 
The nitrotetrazolium blue chloride (NBT)/glycinate calorimetric assay was performed 
for the detection of protein-bound quinones (quinoproteins) in the brain and peripheral 
organs of rats in experiment one and in the cerebellum in experiment two, as previously 
described (Capela et al 2007a). Lysates in RIPA buffer with 50 µg of protein in the case of 
brain areas, or 25 µg of protein for the three peripheral organs, was added to 2 M 
potassium glycinate (pH=10.0) solution (resulting in a final volume of 250 µL). A NBT 
reagent solution (0.24 mM NBT in 2 M potassium glycinate, pH=10.0) was prepared and 
500 µL was added to the protein containing solution. This was followed by an incubation 
under agitation at room temperature, for 3 h protected from light. The reaction between 
quinoproteins and NBT formed a blue-purple coloured complex, and its absorbance was 
measured at 530 nm in a 96-well microplate reader (Biotek PowerWaveX plate reader, 
VT, USA). The results were expressed in OD per mg of protein. 
 
 
3.9. Assessment of protein carbonylation 
 
Protein carbonyls, an index of protein oxidation, were determined, as previously 
described (Barbosa et al 2012). After protein determination all samples were diluted down 
to a final protein concentration of 0.1 mg/mL in complete RIPA. In tubes, 200 µL of 12% 
SDS (w/v) was added to 200 µL of samples containing 20 µg of protein. Samples were 
then incubated with 400 µL of a freshly made solution of 20 mM 2,4-
dinitrophenylhydrazine [DNPH, in 10% trifluroacetic acid (v/v)] for 30 min, at room 
temperature protected from the light. Afterwards, the samples were neutralized with 300 
µL of neutralization solution [18% β-mercaptoethanol (v/v) in 2 M Tris, pH=7.0] followed by 
centrifugation for 2 min at 13,000 rpm (4ºC). The supernatants were diluted down to a 
final protein concentration of 2 µg/mL using PBS as a diluent solution. Before sample 
loading, the nitrocellulose membrane was hydrated in 10% methanol for a few seconds. A 
volume of 100 µL of the derivatized proteins (0.2 µg) was loaded into nitrocellulose 
membranes (Hybond ECL, Amersham Pharmacia Biotech), under vacuum, using a slot 
blot apparatus. Next, the membranes were washed in TBS-T [20 mM Tris base, 300 mM 
NaCl and 0.05% Tween 20 (v/v), pH=8.0], followed by blocking in the blocking buffer 
solution [5% milk (w/v) in TBS-T] for 1 h, under agitation, at room temperature. The 
membranes were then incubated with the primary antibody (rabbit polyclonal anti-DNP, 
1:1000, Molecular Probes A-6430) overnight, at 4ºC. After washing, five times under 
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agitation for 10 min each, with TBS-T, the membranes were incubated with the secondary 
antibody (anti-rabbit IgG-peroxidase, 1:2000, Amersham Pharmacia Biotech) for 1 h, at 
room temperature, under agitation. Antibodies were diluted in blocking buffer. After three 
washes (10 min each) with TBS-T, immunoreactive bands were visualized using the 
Clarity™ Western ECL Substrate, according to the supplier‘s instructions. Digital images 
were acquired using a Molecular Imager® ChemiDocTM XRS+ System (Bio-Rad 
Laboratories, CA, USA) and analysed with Image LabTM Software (Bio-Rad Laboratories, 
CA, USA). Optical density results were expressed as % of control values.   
 
 
3.10. Histology treatment and optical microscopy analysis 
 
The sections of circa 2 mm of heart, kidney and liver were kept on ice in a 4% 
paraformaldehyde solution in PBS for fixation. The dehydration, clearing and paraffin 
embedding were next performed, and the obtained samples were sectioned with a 5 µm 
thickness using a manual rotator microtome Leica RM2125 (Wetzlar, Germany). In these 
sections the hematoxylin/eosin staining was done as follows: 5 min xylene (2x), 5 min 
ethanol 100%, 5 min ethanol 95%, 5 min ethanol 80%, 5 min ethanol 75%, 5 min H2O, 8-
10 min hematoxylin, 5 min running water, 5 min eosin, 5 min ethanol 95%, 5 min ethanol 
100%, 5 min xylene and, finally, mounted in HistoFluid. All preparations were analysed 
and photographed using a Carl Zeiss Imager A1 light microscope equipped with AxioCam 
MRc 5 digital camera (Oberkochen, Germany).  
 
 
3.11. Determination of caspases-3, -8 and -9 activities  
 
The assessment of each caspase activity in the liver, heart and kidneys of the 
animals in experiment one was made by a fluorescent assay for tissues as previously 
described (Maianski et al 2004), with some modifications. The tissues were thawed and 
then homogenized with a Potter A561 in complete caspase lysis buffer. The samples were 
centrifuged at 13,000 rpm, for 30 min at 4ºC, and the supernatant was collected to new 
tubes placed on ice. In a black 96-well plate, 50 µL of cell lysates and 200 µL of assay 
buffer (100 mM NaCl, 50 mM HEPES, 1 mM EDTA, 10% glycerol, 0.1% CHAPS, 10 mM 
DTT, pH=7.4) were added. For negative control, 50 µL of assay buffer was added to the 
plate, instead of the 50 µL of cell lysates. To each well 10 µL of each substrate was 
added. The substrate for caspase-3 was Ac-DMQD-AMC, the substrate for caspase-8 
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was Ac-IETD-AMC, and the substrate for caspase-9 was Ac-LEHD-AMC. All substrates 
were used in a final concentration per well of 100 µM. The plates were incubated at 37ºC, 
protected from the light for 24 h and the fluorescence (excitation 360  nm / emission 460 
nm) was read using a microplate reader Biotech Synergy HT (VT, USA). Results were 
normalized to the amount of protein of each sample added to the well. 
 
 
3.12. Protein quantification 
 
The protein content in the collected samples was measured according to a method 
previously described by Lowry (Lowry et al 1951). Protein standards were prepared with 
BSA in 0.3 M NaOH, and the calibration curve ranged from 25 to 250 μg/mL. To a 96-well 
microtiter plate was added, in triplicates, 50 μL of samples, standards or blanks, followed 
by the addition of 100 μL of freshly prepared reagent (reagent solution: 9.8 mL of 2% 
Na2CO3, 100 μL of 2% sodium potassium tartrate and 100 μL of 1% CuSO4). After 10 min 
in the dark, 100 μL of extemporaneously prepared Folin–Ciocalteu reagent [Folin–
Ciocalteu in H2O (1:14)] was added to each well. The plate was kept protected from light 
for 20 min and the absorbance was measured in a 96-well microplate reader (Biotek 
PowerWaveX plate reader, VT, USA) at 750 nm.  
Regarding the samples containing high detergent concentrations or reducing agents 
(namely complete RIPA buffer or caspase lysis buffer), the DCTM Protein Assay kit from 
Bio-Rad (CA, USA) was used, according to the manufacturer‘s instructions.  
 
 
3.13. Statistical analysis 
 
Results are presented as mean ± standard deviation. When two groups were 
compared, the t-test was used for data that followed a normal distribution or the Mann-
Whitney Rank Sum test, if data did not pass the normality tests. Regarding the statistical 
analysis of the temperature, as well as animal weight, food and water intake of experiment 
two, the two-way analysis of variance (ANOVA) with repeated measurements was used, 
followed by Bonferroni post-hoc test, once a significant p was achieved. Statistical 
significance was accepted at p values less than 0.05. 
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4. RESULTS 
 
4.1. Experiment 1 
 
4.1.1 MDMA binge administration led to hyperthermia in 
adolescent rats and had no effect on body weight gain and food or 
water intake  
 
Three MDMA doses were given to the animals (each dose 5 mg/kg i.p., every 2 h) 
and the first dose did not cause significant changes in body temperature (Figure 6). After 
the second dose of MDMA, the MDMA-treated adolescent rats had a significantly higher 
body temperature when compared to the control group (p<0.0001). Temperature persisted 
significantly higher for almost 2 h after the third dose in treated animals. The temperature 
of MDMA-treated animals never surpassed 39ºC even after the third MDMA dose (Figure 
6). The temperature was also measured 24 h post-MDMA binge administration and no 
differences in the temperature between controls and MDMA-treated rats were observed 
(data not shown).  
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Figure 6 – Temperature monitoring during 7 h of adolescent rats treated with three administrations of NaCl 
0.9% i.p. (control) or 5 mg/kg MDMA i.p. (MDMA-treated). Results in degrees Celsius (ºC) are presented as 
means ± standard deviation, from seven animals in each group. Statistical comparisons were made using two-
way ANOVA repeated measurements followed by the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001 treatment vs. control). 
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Regarding the body weight gain per day, food or water intake (per day and per 
weight) no differences were observed between control and MDMA-treated rats. In fact, 
there was a decrease in the body weight of animals in both groups (Figure 7A), possibly 
as a result of the animal stress due to the manipulation. The food consumption was similar 
in both control and MDMA-treated animals (Figure 7B). However, data showed a tendency 
for an increased water intake in animals that received the three MDMA doses, but it did 
not reach statistical significance (p=0.057) (Figure 7C).   
 
 
Figure 7 – Body weight gain per day (A), food (B) or water (C) intake per day and per weight of animal of 
control and MDMA-treated rats. Results expressed in g / day or g / day / g are presented as means ± standard 
deviation from seven animals in each group. Statistical comparisons were made using the t-test (p > 0.05 
treatment vs. control). 
 
4.1.2. The weight of the organs liver, heart and kidneys was not 
altered by MDMA administration 
 
Each core organ (kidney, heart, liver and brain) had their weight registered and the 
weight ratio of each organ was taken to brain weight. No significant differences were 
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observed between MDMA-treated rats and the control group concerning the liver weight / 
brain weight ratio, heart weight / brain weight ratio and kidneys weight / brain weight ratio 
(Table 6). 
 
Table 6 – Liver weight / brain weight ratio, heart weight / brain weight ratio, and kidney weight / brain weight 
ratio of control and MDMA-treated rats. 
  Control  MDMA 
Liver weight / Brain 
weight ratio  
3.42 ± 0.17 3.15 ± 0.36 
Heart weight / Brain 
weight ratio  
0.33 ± 0.03 0.32 ± 0.05 
Kidneys weight / Brain 
weight ratio  
0.69 ± 0.03 0.66 ± 0.07 
Data are presented as means ± standard deviation, and were obtained from seven animals in each group. The 
mean brain weight of control animals was 1.57 ± 0.04, and of MDMA-treated was 1.63 ± 0.05. Statistical 
comparisons were made using the t-test for the heart weight / brain weight ratio levels and the Mann-Whitney 
Rank Sum test for the liver weight / brain weight ratio and kidney weight / brain weight ratio levels (p > 0.05 
treatment vs. control). 
 
4.1.3. MDMA binge administration to adolescent rats did not 
promote alterations on levels of GSHt, GSSG, GSH and GSH/GSSG 
ratio in the brain areas  
 
In table 7, the levels of GSHt, GSSG, GSH and GSH/GSSG ratio in the cerebellum, 
hippocampus, cortex, and striatum of the animals can be observed. There were no 
significant alterations of all these parameters in the referred brain areas of MDMA-treated 
rats when compared to controls.   
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Table 7 – Total glutathione (GSHt), oxidized glutathione (GSSG), reduced glutathione (GSH) and GSH/GSSG 
ratio levels in cerebellum, hippocampus, cortex, and striatum of adolescent rats. 
CEREBELLUM 
 
Control MDMA 
GSHt 13.32 ± 0.69 12.34 ± 2.80 
GSSG 0.51 ± 0.12 0.47 ± 0.21 
GSH 12.29 ± 0.80 11.40 ± 2.67 
GSH/GSSG ratio 25.20 ± 6.52 28.77 ± 12.21 
      
HIPPOCAMPUS 
 
Control MDMA 
GSHt 21.17 ± 1.22 22.87 ± 3.46 
GSSG 0.42 ± 0.09 0.41 ± 0.18 
GSH 20.33 ± 1.37 22.05 ± 3.72 
GSH/GSSG ratio 50.30 ± 12.72 50.26 ± 19.37 
      
CORTEX 
 
Control MDMA 
GSHt 18.60 ± 1.78 17.93 ± 1.70 
GSSG 0.30 ± 0.05 0.27 ± 0.07 
GSH 18.00 ± 1.77 17.39 ± 1.67 
GSH/GSSG ratio 61.44 ± 10.67 68.60 ± 18.71 
      
STRIATUM 
 
Control MDMA 
GSHt 20.70 ± 6.14 20.49 ± 4.68 
GSSG 0.45 ± 0.22 0.35 ± 0.04 
GSH 19.79 ± 5.88 19.78 ± 4.69 
GSH/GSSG ratio 47.49 ± 16.60 56.76 ± 14.98 
Data of GSHt, GSSG and GSH levels, in nanomol per mg of protein (nmol / mg protein), and the GSH/GSSG 
ratio are presented as means ± standard deviation. Data were obtained from six to seven animals in each 
group. Statistical comparisons were made using the t-test for GSHt and GSH levels in hippocampus, cortex 
and striatum, GSSG levels in cerebellum, hippocampus and cortex and GSH/GSSG ratio levels in cortex and 
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striatum; the Mann-Whitney Rank Sum test was used for GSHt and GSH levels in cerebellum, GSSG levels in 
striatum and GSH/GSSG ratio levels in cerebellum and hippocampus (p > 0.05 treatment vs. control). 
 
4.1.4. ATP content in cortex was decreased 24 hours after the 
binge MDMA administration to adolescent rats  
 
Twenty-four hours after a MDMA binge administration, the ATP levels presented no 
significant changes in cerebellum, hippocampus and striatum, as can be seen in Figure 
8A, B and D, respectively. Importantly, there were significant decreases in the cortex ATP 
content of the MDMA-treated group (p=0.007) (Figure 8C). 
 
 
Figure 8 – ATP content in the cerebellum (A), hippocampus (B), cortex (C) and striatum (D) after MDMA 
administration to adolescent rats. Results, in nanomol per mg of protein (nmol / mg protein), are presented as 
means ± standard deviation, and were obtained from seven animals in each group. Statistical comparisons 
were made using the t-test (**p < 0.01 treatment vs. control).  
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4.1.5. MDMA administration to adolescent rats had no influence 
on quinoprotein levels in the brain areas 
 
In cerebellum, hippocampus, cortex and striatum no differences were found between 
controls and MDMA-treated animals regarding quinoprotein levels (Table 8).  
 
Table 8 – Quinoprotein levels in the cerebellum, hippocampus, cortex and striatum of controls and MDMA-
treated adolescent rats. 
QUINOPROTEIN (OD / mg protein) 
  Control  MDMA 
Cerebellum 5.93 ± 0.42 5.95 ± 0.29 
Hippocampus 6.01 ± 0.78 6.09 ± 0.71 
Cortex 5.54 ± 0.70 5.73 ± 0.50 
Striatum 5.76 ± 0.20 5.78 ± 0.15 
Data of quinoprotein levels, in optical density per mg of protein (OD / mg protein), are presented as means ± 
standard deviation, and were obtained from seven animals in each group. Statistical comparisons were made 
using t-test for the quinoprotein levels in cerebellum and striatum, and Mann-Whitney Rank Sum test for 
quinoprotein levels in hippocampus and cortex (p > 0.05 treatment vs. control). 
 
4.1.6. Protein carbonylation was not altered in the brain areas 
by MDMA binge administration 
 
The levels of protein carbonylation in the cerebellum, hippocampus, cortex and 
striatum of adolescent rats were also determined. As presented in Table 9, there were no 
significant alterations in the protein carbonyl levels 24 h after MDMA treatment, in the four 
brain areas, when comparing controls. 
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Table 9 – Protein carbonylation in the cerebellum, hippocampus, cortex and striatum of controls and MDMA-
treated adolescent rats. 
PROTEIN CARBONYLATION (% of control) 
  Control  MDMA 
Cerebellum 100 ± 28 95 ± 20 
Hippocampus 100 ± 12 101 ± 10 
Cortex 100 ± 29 88 ± 13 
Striatum 100 ± 54 109 ± 46 
Data of protein carbonylation, in percentage of controls (% of control), are presented as means ± standard 
deviation, and was obtained from seven animals in each group. Statistical comparisons were made using t-
test for protein carbonylation in cerebellum, hippocampus and cortex, and Mann-Whitney Rank Sum test for 
protein carbonylation in striatum (p > 0.05 treatment vs. control). 
 
4.1.7. MDMA administration to adolescent rats had no effect on 
plasma AST, ALT, CK-MB and CK-R levels   
 
The plasma levels of CK-R, CK-MB, AST and ALT-R were measured as biomarkers 
of liver or heart integrity (Table 10). The administration of MDMA to adolescent rats did 
not promote significant changes in these parameters when compared to the control group. 
The ratio AST/ALT was also calculated, but no significant differences among groups were 
found (data not shown). 
 
Table 10 – Plasma levels of creatine kinase (CK-R), creatine kinase-MB (CK-MB), aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) of control and MDMA-treated rats. 
  Control  MDMA 
CK-R (U/L) 203 ± 77 200 ± 76 
CK-MB (U/L) 340 ± 139 306 ± 133 
AST (U/L) 39 ± 18 46 ± 19 
ALT (U/L) 34 ± 25 29 ± 4 
Data of CK-R, CK-MB, AST and ALT plasma levels are presented as means ± standard deviation, and were 
obtained from seven animals in each group. Statistical comparisons were made using the t-test for CK-R, CK-
MB and AST levels, and the Mann-Whitney Rank Sum test for ALT levels (p > 0.05 treatment vs. control). 
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4.1.8. MDMA induced vacuolization, oedema and vascular 
congestion in the peripheral organs, 24 hours after the exposure  
 
The histologic examination of peripheral organs (liver, heart and kidneys) of control 
and MDMA-treated rats was performed by means of optical microscopy. The 
representative structural alterations can be observed in Figures 9, 10 and 11.  
The control group showed a preserved liver tissue structure, despite the slight cellular 
vacuolization observed in the periportal regions (Figure 9A and B). The MDMA-treated 
rats presented a marked cellular vacuolization observed in the periportal regions, and 
sinusoidal dilatation with periportal and centrilobular vascular congestion (Figure 9C and 
D). No necrotic zones or interstitial inflammatory cell infiltration were observed in both 
groups.  
 
 
Figure 9 – Optical micrographs of liver sections from control (A and B) and MDMA-treated rats (C and D) 
stained with hematoxylin/eosin. C and D showed sinusoidal dilatation with a marked cellular vacuolization in 
the periportal regions. 
 
In the histological analysis of the heart, both controls (Figure 10A and B) and 
MDMA-treated (Figure 10C and D) animals revealed no signs of necrosis or interstitial 
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inflammatory cell infiltration, presenting both groups a normal tissue organization. In the 
experimental group, animals presented random signs of cardiomyocyte oedema, 
particularly in the sub-endocardic region (Figure 10C and D).  
 
 
Figure 10 – Optical micrographs from heart sections of controls (A and B) and MDMA-treated rats (C and D) 
stained with hematoxylin/eosin. In C and D scattered cardiomyocytes with signs of intracellular oedema can 
be observed, as identified by the reduced cytoplasmic staining. 
 
The renal tissue organization remained preserved in the control group, without signs 
of cellular damage (Figure 11A and B). However, the MDMA-treated group presented 
scattered interstitial oedema, detected by the enlarged space between the tubular 
structures, and signs of vascular congestion (Figure 11C and D). No necrotic zones or 
interstitial inflammatory cell infiltration were observed in both groups.  
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Figure 11 – Optical micrographs of kidney sections from controls (A and B) and MDMA-treated rats (C and D) 
stained with hematoxylin/eosin. In C and D a slight interstitial oedema, detected by the enlarged space 
between the tubular structures, can be observed. 
 
4.1.9. GSHt, GSSG, GSH and GSH/GSSG ratio remained 
unchanged in liver, heart, and kidneys of adolescent rats after 
MDMA administration  
 
The levels of GSHt, GSSG, GSH and GSH/GSSG ratio in the liver, heart and kidneys 
in control and MDMA-treated animals can be observed in Table 11. No differences were 
found for all these parameters in the three organs, between the group that received the 
binge MDMA administration and the control group.   
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Table 11 – Total glutathione (GSHt), oxidized glutathione (GSSG), reduced glutathione (GSH) and 
GSH/GSSG ratio in liver, heart, and kidneys of control and MDMA-treated adolescent rats. 
LIVER 
 
Control  MDMA 
GSHt 19.31 ± 1.96 18.51 ± 2.61 
GSSG 0.60 ± 0.13 0.62 ± 0.14 
GSH 18.10 ± 2.04 17.28 ± 2.38 
GSH/GSSG ratio 31.46 ± 9.22 28.68 ± 4.46 
      HEART 
 
 
Control  MDMA 
GSHt 9.66 ± 1.30 9.53 ± 1.70 
GSSG 0.53 ± 0.14 0.59 ± 0.23 
GSH 8.60 ± 1.43 8.35 ± 1.46 
GSH/GSSG ratio 17.62 ± 7.38 15.86 ± 5.93 
      KIDNEYS 
 
Control  MDMA 
GSHt 2.25 ± 0.38 1.93 ± 0.60 
GSSG 0.06 ± 0.02 0.06 ± 0.01 
GSH 2.12 ± 0.34 1.82 ± 0.60 
GSH/GSSG ratio 37.58 ± 11.26 32.39 ± 11.29 
Data of GSHt, GSSG, and GSH levels, in nanomol per mg of protein (nmol / mg protein), and the GSH/GSSG 
ratio are presented as means ± standard deviation, and were obtained from six to seven animals. Statistical 
comparisons were made using the t-test for the GSHt, GSSG, GSH levels in the liver, heart, and kidneys, and 
the GSH/GSSG ratio in the liver, and the Mann-Whitney Rank Sum test for the GSH/GSSG ratio levels in the 
heart and kidneys (p > 0.05 treatment vs. control). 
 
4.1.10. ATP content remained unchanged in the liver, heart, and 
kidneys of rats 24 hours after the MDMA administration 
 
ATP levels were measured in the liver, heart and kidneys of adolescent rats that 
received saline or three doses of MDMA. No significant differences in the ATP content 
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were observed between the two groups in the three referred organs, as can be seen in 
Table 12.  
 
Table 12 – ATP levels in liver, heart, and kidneys of the control and exposed to MDMA groups.  
ATP (nmol / mg protein) 
  Control  MDMA 
Liver 1.60 ± 0.84 1.69 ± 0.38 
Heart 0.63 ± 0.20 0.60 ± 0.27 
Kidneys 1.75 ± 0.62 1.43 ± 0.57 
Results, in nmol per mg of protein (nmol / mg protein), are presented as means ± standard deviation, and 
were obtained from seven animals in each group. Statistical comparisons were made using the t-test for the 
ATP levels in the heart and kidneys, and the Mann-Whitney Rank Sum test for the ATP levels in the liver (p > 
0.05 treatment vs. control).  
 
4.1.11. Protein-bound quinones formation in the liver were 
increased 24 hours after MDMA administration to adolescent rats 
 
In Figure 12, the measurement of protein-bound quinones (quinoproteins) formation 
in the liver, heart and kidneys of control and MDMA-treated animals can be observed. 
There was a significant increase in the hepatic quinoprotein levels in the MDMA-treated 
group (p=0.039) (Figure 12A). However, no significant alterations were found regarding 
this parameter in the heart or kidneys when comparing both groups (Figure 12B and C). 
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Figure 12 – Quinoprotein levels in liver (A), heart (B) and kidneys (C) of control and MDMA-treated 
adolescent rats. Results, in optical density per mg of protein (OD / mg protein), are presented as means ± 
standard deviation, and were obtained from seven animals in each group. Statistical comparisons were made 
using the t-test for the quinoprotein levels in the liver and kidneys and the Mann-Whitney Rank Sum test for 
the quinoprotein levels in the heart (*p < 0.05 treatment vs. control). 
 
4.1.12. Protein carbonylation showed a tendency to increase in 
the adolescent rat kidneys after MDMA administration  
 
In Figure 13, can be observed the results of protein carbonylation in the liver (Figure 
13A), heart (Figure 13B) and kidneys (Figure 13C) of adolescent rats after an i.p. 
administration of three doses of NaCl 0.9% or 5 mg/kg of MDMA. No significant 
differences were found in the levels of protein carbonyls in the liver and heart between 
controls and the MDMA group. However, data showed a tendency for an increase 
(p=0.051) in protein carbonylation in the kidneys, 24 h after the MDMA administration.  
 
 
Part IV: Results 
74 
 
Figure 13 – Protein carbonylation in liver (A), heart (B) and kidneys (C) of control and MDMA-treated 
adolescent rats. Results, in percentage of controls (% of control), are presented as means ± standard 
deviation, and were obtained from six to seven animals in each group. Statistical comparisons were made 
using the t-test for the protein carbonylation in the liver and heart, and the Mann-Whitney Rank Sum test for 
the protein carbonylation in the kidneys (p > 0.05 treatment vs. control). 
 
4.1.13. MDMA administration promoted a decrease in caspase-8 
activity in rats’ liver, while caspase-3 and -9 activities remained 
unaltered  
 
The data concerning the activities of caspase-3, -8 and -9 in liver, heart, and kidneys 
of adolescent rats after administration of MDMA are presented in Table 13. Caspase-8 
activity significantly decreased in the liver of the MDMA-treated rats when compared to 
controls (p=0.038). No differences were found in the activity of this protease either in heart 
or kidneys. The activities of caspase-3 and caspase-9 had no significant alterations in all 
three organs following MDMA administration when compared to the control group.  
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Table 13 – Caspase-3, -8 and -9 activities in liver, heart and kidneys of adolescent rats that received either 
saline or MDMA. 
LIVER 
FU / µg protein Control  MDMA 
Caspase-3 1.19 ± 0.31 1.12 ± 0.31 
Caspase-8 1.00 ± 0.06 0.93 ± 0.20* 
Caspase-9 0.90 ± 0.07 0.86 ± 0.13 
      HEART 
FU / µg protein Control  MDMA 
Caspase-3 0.44 ± 0.05 0.42 ± 0.06 
Caspase-8 0.48 ± 0.08 0.47 ± 0.11 
Caspase-9 0.09 ± 0.02 0.11 ± 0.05 
      KIDNEYS 
FU / µg protein Control  MDMA 
Caspase-3 0.59 ± 0.08 0.56 ± 0.06 
Caspase-8 0.66 ± 0.09 0.62 ± 0.07 
Caspase-9 0.90 ± 0.18 0.79 ± 0.11 
Data of caspase-3, -8 and -9 activities, in fluorescent units per mg of protein (FU / mg protein), are presented 
as means ± standard deviation, and were obtained from seven animals in each group. Statistical comparisons 
were made using the t-test for the caspase-3 activity in the liver, heart and kidneys and caspase-8 and -9 
activities in the heart and kidneys, and the Mann-Whitney Rank Sum test for the caspase-8 and -9 activities in 
the liver (*p < 0.05 treatment vs. control). 
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4.2. Experiment 2 
 
4.2.1. MDMA binge administration led to a higher hyperthermic 
response in aged than adolescent rats  
 
On experiment two, two different populations were used: adolescents and aged 
animals. To adolescent animals were i.p. administered three doses of either MDMA 5 
mg/kg or NaCl 0.9%, and sacrifice was performed seven days after MDMA exposure. In 
adolescent rats, after the first dose of MDMA the increase in temperature was significantly 
higher when compared to controls (p<0.05), being higher in magnitude following the 
second dose (p<0.001), and the temperature persisted high for more than 3 h after the 
third dose (Figure 14A). To aged rats were i.p. administered two doses of either MDMA 5 
mg/kg or NaCl 0.9%, and sacrifice was performed seven days after MDMA exposure. In 
aged rats, a significant increase in temperature occurred only after the second dose 
(p<0.0001) of MDMA that persisted for the following couple of hours (Figure 14B). In 
particular, in aged animals the temperature reached a peak mean near 41ºC after the 
second MDMA dose (Figure 14B), while adolescent animals never surpassed the mean of 
39ºC even after the third MDMA dose (Figure 14A).  
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Figure 14 – Temperature monitoring of adolescent (A) and aged (B) rats for 6 to 7 h after the administration of 
either saline (control) or MDMA (MDMA-treated). Results in degrees Celsius (ºC) are presented as means ± 
standard deviation, from five animals in each group. Statistical comparisons were made using two-way 
ANOVA followed by the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
treatment vs. control). 
 
In Figure 15, the results of the daily temperature of adolescent (Figure 15A) and aged 
(Figure 15B) rats for the following seven days after MDMA exposure are presented. 
Following the day of exposure to MDMA the animal body temperature was monitored daily 
at the same hour of the first administration. No significant differences were observed in 
MDMA-treated adolescent animals when compared to the control group. In aged rats, the 
B 
A 
Part IV: Results 
78 
temperature was significantly elevated in the MDMA-treated animals (p<0.001), 24 h post-
MDMA binge administration. 
 
 
 
Figure 15 – Temperature monitoring of adolescent (A) and aged (B) rats for the seven days after the 
administration of either saline (control) or MDMA (MDMA-treated). Results in degrees Celsius (ºC) are 
presented as means ± standard deviation, from five animals in each group. Statistical comparisons were made 
using two-way ANOVA followed by the Bonferroni post hoc test (***p < 0.001 treatment vs. control). 
 
4.2.2. MDMA treatment induced alterations in the body weight of 
adolescent animals and food and water intake of aged animals 
 
Data of animal body weight gain per day (Figure 16A and B), and food (Figure 16C 
and D) or water (Figure 16E and F) intake, per day and per weight, during the seven days 
post-treatment in adolescent and aged rats, are presented in Figure 16. In the adolescent 
population, there was a significant decrease on the body weight of the MDMA group on 
the first day post-MDMA administration (p<0.05) (Figure 16A). However, no differences 
were observed in this population for both food and water consumption (Figure 16C and E, 
respectively). In contrast to the adolescent rats, in the aged animals there were no 
significant differences in body weight between treated and respective controls (Figure 
16B). However, in the MDMA-treated aged rats, food intake significantly decreased on the 
first day post-MDMA administration (p<0.05), while it significantly increased on the second 
day post-MDMA administration (p<0.01) (Figure 16D), when compared to controls. 
Moreover, in aged rats, the water intake was significantly higher in the MDMA group, 
when compared to controls, in the two consecutive days following the MDMA binge 
administration (p<0.001) (Figure 16F). 
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Figure 16 – (A and B) Body weight gain per day of adolescent (A) and aged (B) rats, respectively, for seven 
days after the treatment day. (C and D) Food intake per day and per weight of animal of adolescent (C) and 
aged (D) rats, respectively, for seven days after the treatment day. (E and F) Water intake per day and per 
weight of animal of adolescent (E) and aged (F) rats, respectively, for seven days after the treatment day. 
Results in g / day or g / day / g are presented as means ± standard deviation, from five animals in each group. 
Statistical comparisons were made using two-way ANOVA followed by the Bonferroni post hoc test (*p < 0.05, 
**p < 0.01 and ***p < 0.001 treatment vs. control). 
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4.2.3. GSHt, GSSG, GSH and GSH/GSSG ratio levels in the 
cerebellum of adolescent and aged rats remained unaltered seven 
days after the MDMA administration 
 
In the cerebellum, no differences were found between controls and MDMA-treated 
groups concerning the levels of GSHt (Figure 17A and B), GSSG (Figure 17C and D), 
GSH (Figure 17E and F) and GSH/GSSG ratio (Figure 17G and H) in both adolescent and 
aged rats, one week after the MDMA administration. Moreover, the levels of GSHt and of 
the GSH/GSSG ratio were very similar in the control groups of aged and adolescent rats. 
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Figure 17 – (A and B) GSHt levels, in nanomol per mg of protein (nmol / mg protein), in cerebellum of 
adolescent (A) and aged (B) rats, respectively, seven days after treatment. (C and D) GSSG levels, in nmol / 
mg protein, in the cerebellum of adolescent (C) and aged (D) rats, respectively, seven days after treatment. (E 
and F) GSH levels, in nmol / mg protein, in the cerebellum of adolescent (E) and aged (F) rats, respectively, 
seven days after treatment. (G and H) GSH/GSSG ratio levels in the cerebellum of adolescent (G) and aged 
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(H) rats, respectively, seven days after treatment. Results are presented as means ± standard deviation, and 
were obtained from five animals in each group. Statistical comparisons were made using the t-test for GSHt, 
GSH and GSH/GSSG ratio levels in adolescent and aged rats and for GSSG levels in aged rats, and the 
Mann-Whitney Rank Sum test for GSSG levels in adolescent rats (p > 0.05 treatment vs. control). 
  
4.2.4. One week after the MDMA administration aged animals 
presented significant decreases in the cerebellum ATP content  
 
In Figure 18, are presented the ATP levels in the cerebellum of adolescent (Figure 
18A) and aged (Figure 18B) rats, one week after the MDMA administration. No 
differences were observed between controls and MDMA-treated animals in the cerebellum 
ATP levels of adolescent rats (Figure 18A). However, in aged animals there was a 
significant decrease of the cerebellum ATP content in the MDMA group (p=0.015) (Figure 
13B). 
 
 
Figure 18 – ATP content in the cerebellum, seven days after treatment, in adolescent (A) and aged (B) rats. 
Results, in nanomol per mg of protein (nmol / mg protein), are presented as means ± standard deviation, and 
were obtained from five animals in each group. Statistical comparisons were made using the t-test (*p < 0.05 
treatment vs. control).   
 
4.2.5. Quinoprotein levels were unaltered in the cerebellum of 
rats one week after MDMA administration 
 
One week after the MDMA binge administration, there were no significant differences 
between controls and MDMA-treated animals in the protein-bound quinones 
(quinoproteins) in the cerebellum of either adolescent or aged rats. The data regarding the 
measurement of quinoproteins is presented in Figure 19.   
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Figure 19 – Quinoprotein levels in the cerebellum, seven days after treatment, in adolescent (A) and aged (B) 
rats. Results, in optical density per mg of protein (OD / mg protein), are presented as means ± standard 
deviation, and were obtained from five animals in each group. Statistical comparisons were made using t-test 
for quinoprotein levels in adolescent rats, and Mann-Whitney Rank Sum test for quinoprotein levels in aged 
rats (p > 0.05 treatment vs. control). 
 
4.2.6. Seven days after MDMA administration no significant 
differences were found in cerebellum protein carbonyl levels of rats 
 
In Figure 20, are presented the results concerning the protein carbonylation in the 
cerebellum of adolescent (Figure 20A) and aged (Figure 20B) rats. Seven days after the 
binge administration of MDMA, no significant differences were found between the control 
and the MDMA-treated group in either adolescent or aged rats. 
 
 
Figure 20 – Protein carbonylation in the cerebellum, seven days after treatment, in adolescent (A) and aged 
(B) rats. Results, in percentage of control (% of control), are presented as means ± standard deviation, and 
were obtained from five animals in each group. Statistical comparisons were made using t-test for protein 
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carbonylation in adolescent rats, and Mann-Whitney Rank Sum test for protein carbonylation in aged rats (p > 
0.05 treatment vs. control). 
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5. DISCUSSION AND CONCLUSIONS 
 
5.1. Experiment 1 
 
5.1.1. MDMA-induced hyperthermia in adolescent animals 
 
Hyperthermia is an important sign following MDMA administration, therefore we 
controlled the body temperature of rats in both experiments. In experiment one, MDMA 
administration promoted a significant increase in the rats‘ body temperature, as expected. 
The MDMA use, particularly, the hyperthermic response may lead to several physiological 
changes, and, for that reason, we also assessed the body weight gain, as well as the food 
and water consumption. The adolescent animals‘ body weight decreased in both controls 
and MDMA-treated animals in experiment one, probably as a result of the stress induced 
by the manipulation during the experiment, and no differences were found between the 
groups. No significant differences were also found in terms of food or water consumption 
in the adolescent animals, 24 h after the MDMA exposure. 
Hyperthermia is commonly associated with recreational use of MDMA and body 
temperatures of about 43ºC in humans and several associated fatalities have been 
reported (Green et al 2004a, Henry 1992, Jaehne et al 2007). As previously referred, this 
drug is often used in parties with elevated ambient temperature and crowded rooms, 
where physical exertion (dancing) and dehydration are common. These aspects can 
contribute to an elevated body temperature of consumers (Henry 1992, Irvine et al 2005, 
Patel et al 2005). Physical activity, peripheral vasoconstriction, loss of thermoregulatory 
mechanisms at the CNS, loss of body signal perception (like thirst and exhaustion), 
euphoria, increased muscle tone, and heat production are the aspects that mainly 
contribute to the hyperthermic effects associated with MDMA use (Capela et al 2009). 
Studies in laboratory animals reproduce the hyperthermic response seen in humans, and 
several studies reported that MDMA evokes an hyperthermic response in rats and mice 
(Alves et al 2007, Carvalho et al 2002, Colado et al 1993). Furthermore, hyperthermia is 
also a factor that contributes for the neurotoxic effects of MDMA in rats (Malberg & Seiden 
1998). Several studies reported that the prevention of the MDMA-induced hyperthermia 
resulted in a reduction of the serotonergic neurotoxicity promoted by this drug (Colado et 
al 1999, Farfel & Seiden 1995, Malberg et al 1996). Moreover, in vitro studies using 
neuronal cultures demonstrated that the neurotoxic actions induced by MDMA are 
potentiated by hyperthermia (Barbosa et al 2014, Capela et al 2007a, Capela et al 2006a, 
Capela et al 2006b). A study conducted with adult male Wistar rats (ten week old), treated 
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with the same MDMA binge regimen (5 mg/kg x 3, i.p., every 2 h) used in the experiments 
performed within this dissertation, showed that the administration of the drug in reduced 
ambient temperature (15ºC) blocked the hyperthermic response and the long-term 
depletion of 5-HT, found at normal environmental temperature (21.5ºC). These data 
confirm the existence of a relation between the body temperature and MDMA serotonergic 
neurotoxicity (Goni-Allo et al 2008). Herein, this binge regimen of MDMA in adolescent 
Wistar rats (PND 40) did not promote serotonergic toxicity (Feio-Azevedo et al Submitted), 
ruling that hyperthermia per se is not a triggering factor for neurotoxic events. 
Nonetheless, MDMA-induced hyperthermia certainly potentiates the toxicity observed in 
the brain areas and also the peripheral organs.  
 
5.1.2. Acute brain changes induced by MDMA in adolescent 
animals 
 
Though the MDMA binge scheme used in this study was previously shown to be non-
neurotoxic to the serotonergic and dopaminergic system of PND 40 adolescent rats (Feio-
Azevedo et al Submitted), we evaluated several other brain changes. We aimed to verify if 
this MDMA regimen could promote oxidative stress or ATP decreases in the brain, despite 
not promoting neurotoxicity to the monoaminergic system.  
In this dissertation, no differences were found in glutathione levels in the brain areas 
of the rat, namely cerebellum, hippocampus, cortex and striatum, 24 h after MDMA binge 
administration. To the best of our knowledge, the glutathione levels presented in this 
thesis were for the first time obtained in adolescent rats, 24 h after a non-neurotoxic 
MDMA regimen to the serotonergic system. Other studies have evaluated the glutathione 
brain levels following neurotoxic regimens of amphetamines at different time-points. 
Riezzo and co-workers demonstrated that a single dose of MDMA (20 mg/kg, i.p.) to 
Wistar rats (200-250 g), promoted significant decreases of GSH/GSSG ratio, 3 and 6 h 
after the MDMA exposure, in several brain areas (frontal cortex, hippocampus and 
striatum) (Riezzo et al 2010). A study in nine week old Swiss Webster mice showed that 
METH (5 mg/kg x 3, i.p., 3 h apart) promoted decreases in the GSH levels 5 to 13 days 
following METH exposure, in the frontal cortex, striatum, amygdala and hippocampus 
(Achat-Mendes et al 2007). Another study in mice assessed the GSH levels after MDMA 
administration. Male C57 black mice, with ages from nine to ten weeks old, received 2.5 
mg/kg of MDMA (i.p., every day, for five days) and levels of GSH were measured 
immediately after the last exposure to the drug. The GSH content was significantly 
decreased in the hippocampus (Frenzilli et al 2007). Major differences from the three 
reports mentioned above to the present study are the use of older animals and the 
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administration of different doses. A threshold of MDMA might be necessary to promote 
GSH decrease or the effect at this marker might be transient. On the other hand, 
adolescent animals might be less susceptible to changes in glutathione redox status. 
In this dissertation, no differences were found in protein-bound quinone formation, 
between controls and MDMA-treated groups in the rat brain areas (cerebellum, 
hippocampus, cortex and striatum) 24 h after MDMA binge administration. No previous 
studies in vivo were found that evaluate this parameter after MDMA administration. Nine 
weeks-old BALB/c mice received four injections of 4 mg/kg of METH (i.p., 2 h apart) and, 
3 and 14 days after the repeated administration of METH, elevated quinoprotein levels 
were observed in the striatum along with decreases in DAT immunoreactivity (Miyazaki et 
al 2006). That paper also reported that METH promoted in dopaminergic CATH.a cells 
neuronal cell death and increased quinoprotein levels, in a dose-dependent fashion. 
Altogether, the results observed confirm the importance of DA-dependent quinone 
formation in the neurotoxicity of abuse drugs, namely METH (Miyazaki et al 2006). Two 
studies from our group, conducted in vitro, showed that MDMA or its metabolites were 
able to increase quinoprotein formation in the brain (Barbosa et al 2012, Capela et al 
2007a). In this thesis it became demonstrated that MDMA in rats was not able to increase 
protein-bound quinone formation in the brain, up to 24 h after its administration, in a 
regimen that does not promote monoaminergic neurotoxicity.         
MDMA metabolites can oxidize into ortho-quinones that may produce reactive oxygen 
species (ROS) and cause oxidative stress through the formation of oxidized cellular 
macromolecules, leading to structural and functional modifications such as protein 
carbonylation (Carvalho et al 2004a, Carvalho et al 2004b, Carvalho et al 2004c). The 
MDMA dosage regimen used in this thesis was not able to promote any alterations in 
protein carbonylation. Alves and co-workers evaluated the MDMA-induced neurotoxicity in 
mitochondria isolated from several brain regions of adolescent male Wistar rats at PND 
45. The administration of a neurotoxic dose of MDMA (10 mg/kg x 4, i.p., every 2 h) 
promoted increases in the levels of protein carbonyls in brain mitochondria, two weeks 
after MDMA exposure (Alves et al 2007). We used a moderate dosage regimen of MDMA 
and the protein carbonylation levels were measured 24 h after the exposure to the drug, 
so it remains to be verified if later time-points would be crucial in this biochemical marker. 
Another study conducted with mouse brain synoptosomes found that exposure to MDMA 
metabolites was able to increase protein carbonyl levels, but not MDMA itself (Barbosa et 
al 2012).    
 The present study did not find any significant role for oxidative stress related 
changes in the rat adolescent brain, 24 h following administration of MDMA in human 
relevant doses.  
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MDMA hepatic metabolism plays an important role in the toxicity of this drug, since it 
can result in the formation of several highly reactive metabolites, like quinone 
intermediates, that can subsequently produce ROS and lead to oxidative stress (Capela et 
al 2009). Several studies reported that MDMA metabolites produce neurotoxicity in 
laboratory animals (Escobedo et al 2005, Jones et al 2005, Miller et al 1996). As 
previously mentioned, the MDMA metabolites N-Me-α-MeDA and α-MeDA can be oxidize 
into ortho-quinones, that can retain the ability to redox cycle and induce oxidative stress 
(Monks & Lau 1997). These metabolites can conjugate with thiols and glutathione 
originating adducts. Jones and colleagues showed that glutathione and N-acetylcysteine 
(NAC) conjugates of N-Me-α-MeDA are present in striatum of rats after an injection of 
MDMA (20 mg/kg, s.c.). The mentioned NAC conjugates produce serotonergic 
neurotoxicity when injected directly into the striatum, suggesting that these metabolites 
are capable of causing neurotoxic damage (Jones et al 2005). A study in cultured rat 
cortical neurons tested the neurotoxicity of MDMA metabolites, N-Me-α-MeDA, α-MeDA, 
and their glutathione and NAC conjugates. The MDMA thioether metabolites increased 
production of reactive species in a time-dependent manner, depleted intracellular GSHt in 
a concentration-dependent manner, and increased protein-bound quinones. NAC, an 
antioxidant, was also able to prevent neuronal death and oxidative stress in that model 
(Capela et al 2007a). 
In this thesis, a significant depletion of the ATP levels in the cortex of the MDMA-
treated rats, 24 h after MDMA binge administration, was found. No alterations were found 
in the other three brain areas (cerebellum, hippocampus and striatum) tested. A study with 
Sprague-Dawley rats (200-275 g), which received four i.p. administrations of 10 mg/kg 
MDMA, 2 h apart, showed decreased ATP content in the striatum 1, 12 and 24 h after the 
exposure, as well as in the hippocampus 12 h after MDMA administration (Darvesh & 
Gudelsky 2005). In another study, a single administration of METH (5 mg/kg, i.p.) to 
adolescent (4 weeks old) Wistar rats, promoted decreases in ATP levels in the brain, 30 
min after the drug administration (Shiba et al 2011). Interestingly, the same study showed 
that 24 h after the exposure to the drug, the ATP levels were normalized to the control 
levels (Shiba et al 2011). In C57BL/6 mice, with ages ranging from eight to ten weeks old, 
showed decreases in striatal ATP levels 1.5 h after multiple METH administration (10 
mg/kg x 4, i.p., 2 h apart). ATP content returned, approximately, to the control levels 24 h 
after the exposure and no decreases were found in the cerebellar cortex and 
hippocampus (Chan et al 1994). When comparing the studies described with the results 
obtained in this thesis, it can be seen that: Darvesh & Gudelsky found differences in the 
ATP content of striatum and hippocampus in older animals and with higher MDMA doses 
than the ones used herein (Darvesh & Gudelsky 2005); meanwhile Shiba and co-workers 
Part V: Discussion and conclusions 
91 
found decreases in the brain ATP levels 30 min after METH administration, but not 24 h 
after the exposure (Shiba et al 2011), as it was the case for Chan and co-workers that 
exposed mice to METH and changes were found 24 h after the administration (Chan et al 
1994). The drug used, the dosage regimen, the animal model, the animals‘ age, and the 
time elapsed until the measurements seem to be important factors regarding the 
impairment in the brains‘ energetic functions. The time-frame for ATP content analysis 
may reveal that at earlier times of exposure a decrease in ATP levels occurs, but at later 
periods no changes are found, perhaps ruling for a transitory effect at least in adolescent 
animals.  
 
5.1.3. Organs-related changes promoted by acute exposure to 
MDMA in adolescent animals 
 
In experiment one was observed an increase in protein-bound quinone formation in 
the liver of MDMA-treated rats, 24 h after MDMA exposure. No differences in quinoprotein 
levels in the heart and kidneys of the exposed rats were observed. These results might be 
related to the fact that the metabolism of this drug is primarily hepatic, which generates 
catechol metabolites that can promote the formation of protein-bound quinones. In vitro 
studies in rat cardiomyocytes and hepatocytes showed that the MDMA metabolism can 
result in ortho-quinones, and subsequent oxidative stress (Carvalho et al 2004a, Carvalho 
et al 2004b, Carvalho et al 2004c). The increased protein-bound quinone formation in the 
liver of rats is an indicator of possible oxidative stress in this organ, 24 h after MDMA, 
possibly caused by the catechol MDMA metabolites, and possibly a sign of higher 
susceptibility towards MDMA toxicity. 
Glutathione is an important antioxidant that plays a major role in protecting against 
oxidative stress. In adolescent rats, no differences were found neither in the GSHt levels 
nor in the GSH/GSSG ratio in the liver, heart and kidneys. An in vivo study in rats reported 
decreases in hepatic GSH content after MDMA repeated exposure (Beitia et al 2000). 
Acute administration of a single dose of MDMA (20 mg/kg, i.p.) had no significant effect in 
hepatic GSH levels of Wistar rats (200-220 g), 3 or 6 h after the MDMA administration. 
However, with a repeated MDMA administration (20 mg/kg x 2, i.p., for four days), GSH 
content in the liver of the MDMA-treated rats was significantly decreased, 3 or 6 hours 
after the last MDMA exposure. Seven days later, the GSH content returned to the control 
levels (Beitia et al 2000). Another study in rats (200-250 g) reported decreases in cardiac 
GSHt levels after a single MDMA administration (20 mg/kg, i.p.), 3 and 6 h after the 
exposure. No differences were found in GSSG levels (Cerretani et al 2008). In fact, the 
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heart has unique features that render it a target organ for oxidative stress-related injuries, 
including those related to drug exposure (Costa et al 2013). Several studies conducted in 
vitro with rat and mice hepatocytes demonstrated that one of the toxic events observed 
after exposure to MDMA or MDMA metabolites is the depletion of GSH (Carvalho et al 
2001, Carvalho et al 2004a, Carvalho et al 2004b). N-Me-α-MeDA and α-MeDA incubation 
also resulted in the GSH depletion in cardiomyocytes of rats (Carvalho et al 2004c). In this 
thesis, no differences were found in the GSH levels of the peripheral organs studied, but 
the doses of MDMA were lower than those reported by the previous in vivo studies, and 
the GSH levels were assessed 24 h after the MDMA administration, contrarily to the 3 and 
6 h reported in the referred studies. Additionally, it is possible that at earlier time-points, 
there would be changes in the GSH levels that were transient. In fact, the Beitia and 
colleagues argues, even with high MDMA dose (total cumulative dose of 160 mg/kg) that 
GSH levels changes in the liver might be transient (Beitia et al 2000). 
Herein, a tendency to an increase in protein carbonylation in kidneys was observed, 
but it did not reach statistically significance. The liver and heart presented no alterations in 
this oxidative stress parameter. Protein carbonylation degree is an indicator of protein 
oxidation. An in vivo study reported increases in protein carbonyls in the liver of rats 
treated with MDMA (10 mg/kg, p.o., twice daily, for two days), 12 h after the exposure to 
the drug (Upreti et al 2011). Another study reported increases in protein carbonylation in 
liver and kidneys of mice (7 weeks old). METH administration (10 mg/kg, i.p., every 2 h, 
for 8 h) promoted significant increases in protein carbonyls in liver and kidneys of mice, 24 
h after the last administration (Zhang et al 2012). Although these studies were performed 
in different animals using a different dose regimen and not only with MDMA, they 
corroborate the tendency of increased protein carbonylation in peripheral organs after 
administration of amphetamines.  
Using an MDMA regimen comparable to human adolescent doses, and using 
adolescent rats, the present study only found augmented quinoprotein levels in the liver of 
MDMA-treated rats, 24 h following administration of MDMA. No changes could be seen in 
other parameters, such as glutathione levels and protein carbonylation in the peripheral 
organs of adolescent rats. Altogether these results imply that a threshold MDMA dose 
exists, possibly above the one herein used, to promote very significant oxidative stress-
related damage. Additionally, adolescent animals could be less susceptible to oxidative 
stress related changes than adult animals. The time-point for oxidative stress related 
parameters evaluation seems also to be important.  
In the peripheral organs, we were not able to find alterations in the ATP content of the 
MDMA-treated rats. In vitro studies in freshly isolated rat hepatocytes reported decreases 
of the ATP content induced by high concentrations of MDMA and its metabolites in a 
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concentration- and time-dependent manner (Beitia et al 1999, Carvalho et al 2004b, 
Nakagawa et al 2009). A study in isolated adult rat cardiomyocytes also reported ATP 
depletions after exposure to high concentrations of MDMA metabolites (Carvalho et al 
2004c). No in vivo studies were found in the literature, reporting the ATP levels in the 
peripheral organs of laboratory animals following MDMA exposure. The present results 
imply that MDMA moderate doses, which can be comparable to those used by humans, 
do not acutely impair the energetic status of peripheral organs of adolescent rats. 
In this thesis, the histological examination of the liver of MDMA-treated rats found 
marked cellular vacuolization in the periportal regions, and sinusoidal dilatation with 
periportal and centrilobular vascular congestion. In the heart, punctual signs of 
cardomyocyte oedema, particularly in the sub-endocardic region, were found after MDMA 
exposure. The kidneys of MDMA-treated adolescent rats presented scattered interstitial 
oedema, with dilatation between the nefrotic tubular structures, and signs of vascular 
congestion. In the three organs studied there were no signs of necrosis or interstitial 
inflammatory cell infiltration induced by the drug.  
In experiment one, we found no alterations in the plasma levels of CK-R, CK-MB, 
AST and ALT following MDMA administration to the adolescent rats. Since these 
parameters are biomarkers of liver or heart integrity, the absence of necrosis in the 
histological examination corroborates the data of these plasmatic parameters. Beitia and 
co-workers reported changes in AST and ALT serum activities after MDMA exposure to 
Wistar rats, using higher MDMA doses than our study. AST activity significantly increased 
6 h after a single MDMA dose (20 mg/kg, i.p.) and 3 and 6 h after a repeated MDMA 
administration (20 mg/kg x 2, i.p., for four days), remaining significantly elevated for seven 
days after the last drug administration. The single MDMA dose (20 mg/kg, i.p.) also 
promoted increases in ALT activity 6 h after the administration, while the repeated MDMA 
treatment (20 mg/kg x 2, i.p., for four days) had no effect on ALT activity (Beitia et al 
2000). The intracellular enzymes leakage to extracellular medium is suggestive of 
irreversible damage, being AST and ALT serum activities markers of liver injury, and 
indicators of important cell necrosis. For that reason, in the previous study mentioned, 
Beitia and co-workers also made the histological hepatic examination of the animals. Six 
hours after the acute MDMA administration, researchers observed necrosis on portal 
areas with inflammatory infiltration, and the repeated administration also promoted hepatic 
necrosis and inflammatory infiltrate around the hepatic vein, being more marked 6 h after 
the last administration and being consistent with drug-induced hepatitis. Seven days later, 
no liver changes were reported, raising the possibility that these changes might be 
transient (Beitia et al 2000). A study in humans, also reported a case with a 19 years old 
male that presented morphological signs of acute hepatitis, after the ingestion of two 
Part V: Discussion and conclusions 
94 
―ecstasy‖ tablets, with a full recovery after two months (Brncic et al 2006). In another study 
in rats, researchers reported alterations in cardiac morphology with a single MDMA 
administration (20 mg/kg, i.p.). Six hours after MDMA administration, myocardial necrosis 
was observed, and 16 h after the MDMA administration the heart presented macrophagic 
monocytes around the necrotic myocardial cells. Twenty-four hours later, the referred 
infiltrate became more intense and widespread, and the removal of the necrotic material 
had already begun (Cerretani et al 2008). Other studies in humans reported several 
histopathological evidences of MDMA toxicity to the kidneys of ―ecstasy‖ consumers. 
These case reports demonstrated that MDMA induced tubular degeneration and necrosis 
and inflammatory infiltrates (Bingham et al 1998, Dar & McBrien 1996, Fineschi et al 
1999).  
The absence of severe tissue damage promoted by MDMA to adolescent rats was 
also confirmed by the inexistence of increases in caspases activity in every peripheral 
organ studied, since they are crucial components in apoptotic pathways (Parrish et al 
2013). We found no alterations in caspase-3 and -9 activities, in the three organs, after 
MDMA exposure. The caspase-8 activity remained unaltered in the heart and kidneys of 
the MDMA-treated animals, but the drug promoted decreases in this caspase activity in 
the liver of the treated rats. The caspase-8 activity decrease probably occurred due to an 
attenuation of a natural on-going degenerative process (Kudryashova et al 2012). Tiangco 
and co-workers reported that MDMA exposure to cultured rat striated cardiac myocytes 
caused a repression of caspase-1 and caspase-8 genes, being the adverse effects of 
MDMA not caused by an activation in the apoptotic mechanism (Tiangco et al 2005).  
 
 
5.2. Experiment 2  
 
5.2.1. Age related differences in MDMA-induced hyperthermia 
and in weight, food and water intake 
 
As in experiment one, significant increases in the rats‘ body temperature were also 
observed after the MDMA administration to either adolescent or aged rats. There were 
also differences in the hyperthermic profile of aged and adolescent rats. In the case of 
aged rats only after the second MDMA dose the increase in body temperature could be 
significant, meanwhile in adolescent rats temperature was already significantly higher 
following the first dose. The hyperthermia induced by the MDMA binge administration had 
a higher magnitude in aged rats than in the adolescents. 
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The rats‘ body temperature was also evaluated for the following seven days after the 
exposure, and 24 h post-MDMA administration the temperature of the aged animals was 
significantly elevated, leading to the belief that the animals body temperature possibly 
remained elevated for 24 h after MDMA exposure. In contrast, adolescent rats, in both 
experiments, presented no alterations in body temperature 24 h after MDMA exposure, in 
comparison to controls. This certainly argues for a higher susceptibility of aged rats 
towards MDMA-induced impaired thermoregulation. 
In fact, as previously reported, in experiment two, one of the aged animals didn‘t 
resist to the elevated temperatures that surpassed 41ºC, possibly as a consequence of 
the extreme hyperthermia. As previously reported by Goni-Allo and co-workers, it was 
observed that the same MDMA binge regimen of administration used in our study (5 
mg/kg x 3, i.p., 2 h apart) promoted in adult Wistar rats a death rate of 5% at an 
environmental temperature of 21ºC. Meanwhile if MDMA administration was conducted 
with a single injection of 15 mg/kg (i.p) to the same rat strain, the mortality rate would 
reach 20% at an environmental temperature of 21ºC (Goni-Allo et al 2008). In our study 
conducted with adolescent PND 40 rats, no signs of severe hyperthermia could be seen 
and the MDMA regimen did not cause any death to this population. Thus, it is reasonable 
to assume that animal aging increases the susceptibility for severe MDMA-induced 
hyperthermia. The susceptibility to hyperthermia and death events is certainly dependent 
on the MDMA dose regimen, but also the animal age and strain (Capela et al 2009). 
In experiment two, MDMA promoted a decrease in the body weight of adolescent 
animals, in comparison to controls. Meanwhile, in experiment one the animals‘ body 
weight decreased in both controls and MDMA-treated animals. That probably happened 
due to the fact that the experiments were conducted in different vivarium conditions. In 
experiment one, animals were housed in individually ventilated cages, creating a more 
stressful procedure, meanwhile in experiment two they were housed in normal cages. The 
decrease in body weight is probably related with the anorectic properties of MDMA 
(Cohen 1995). Piper and Meyer showed that the repeated MDMA treatment (10 mg/kg, 
s.c., twice daily, 4 h apart, for 25 days) produced an anorectic effect in adolescent rats 
(Piper & Meyer 2004), corroborating the findings in this thesis. Looking at other 
parameters, no significant differences were found in food or water consumption for the 
adolescent animals in both experiments. Importantly, aged animals of experiment two, 
presented decreases in food consumption 24 h after the MDMA administration and 
increases 48 h post-MDMA administration. Moreover, the aged animals of the experiment 
two, presented increases in water intake in the next 24 and 48 h, after the MDMA 
administration. Aged animals appear to be more susceptible to the MDMA-induced 
physiological changes than the adolescent animals. The higher magnitude of the 
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hyperthermic response in aged animals also supports for the need of these animals to 
increase their water intake. 
 
5.2.2. Age-related changes in cerebellum  
 
MDMA effects in the cerebellum have been scarcely studied and little is known about 
the susceptibility of different aged groups. Thus, in this thesis the neurotoxicity of MDMA 
in cerebellum was assessed, by evaluating its energetic and oxidative stress status, in 
adolescent and old rat animals after MDMA-binge administration. In humans, MDMA 
neurotoxic effects were associated to decreased grey matter in the cerebellum (Cowan et 
al 2003). Cowan and co-workers performed a study with 31 MDMA polydrug human users 
(average age of 21.7 ± 3.3 years old and abstinent from MDMA at least three weeks 
before starting the study) versus 29 non-MDMA users (average age of 24.3 ± 3.5 years 
old) and they compared their brain grey and white matter concentration. They found 
decreases in grey matter concentration in several brain areas, including the cerebellum 
(Cowan et al 2003). Meanwhile, in an experiment conducted with six weeks-old Sprague-
Dawley rats revealed significant decreases in 5-HT and 5-HIAA levels in the rats 
cerebellum, seven days after the exposure to a single MDMA dose (40 mg/kg, i.p.) (Zheng 
& Laverty 1998). Another study in Sprague-Dawley rats (175–200 g) observed significant 
decreases in 5-HT uptake sites, in several brain regions, 18 h and two weeks, following 
the last MDMA administration (20 mg/kg, twice daily, 12 h apart, for four consecutive 
days). In cerebellum, no differences were found in the 5-HT uptake sites with that dose 
regimen (Battaglia et al 1991). Unfortunately, none of the previous mentioned studies 
evaluated the oxidative stress parameters in the cerebellum. 
In the cerebellum, we observed depletion of the ATP content in aged rats, seven 
days after the exposure to MDMA. A study from Shiba and co-workers reported decreases 
in ATP levels in the brain of adolescent (4 weeks old) Wistar rats 30 min after a single 
METH administration (5 mg/kg, i.p.). The same study also showed that 24 h after the 
exposure, ATP brain levels were normalized to control levels (Shiba et al 2011). The 
results presented in this thesis with aged animals reveal that the decrease in the ATP 
levels in the cerebellum seem to be more long lasting, in opposite to the effects in 
adolescent animals described by Shiba and co-workers. As mentioned above, the ATS 
used, the dosage regimen, the animals‘ age, and the time elapsed until the measurements 
seem to be important factors regarding the impairment in the brains‘ energetic functions. 
All the oxidative stress parameters remained unaltered in the cerebellum of both 
adolescent and aged MDMA-treated rats. As previously described for experiment one, 
several studies reported depletions of GSH (Achat-Mendes et al 2007, Frenzilli et al 2007) 
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and ATP (Chan et al 1994, Darvesh & Gudelsky 2005, Shiba et al 2011), and increases in 
quinoproteins (Miyazaki et al 2006) and protein carbonylation (Alves et al 2007), in the 
brain, following the exposure to MDMA or other ATS. However, these studies used 
different dose regimens and the time elapsed until the measurements, as well as the brain 
areas assessed were diverse. Besides, none of the referred studies evaluated the 
oxidative stress related changes in the cerebellum.  
No studies were found regarding the age-related neurotoxicity induced by MDMA in 
cerebellum, although some were found in other brain areas. Some studies suggest that 
young animals are more resistant to immediate neurological damages promoted by 
MDMA. Nevertheless, the long-term effects are scarcely investigated. Klomp and co-
workers administered MDMA (10 mg/kg, s.c., twice daily for four days) to adolescent rats 
at PND 27 and to adult rats at PND 63 (+/- five days), and observed significant reductions 
in 5-HTT binding in several brain regions seven days after the last MDMA administration. 
The reductions were less pronounced in adolescent rats (ranging from 20% to 69%) when 
compared to adult rats (ranging from 35% to 75%). Besides, the degree of 5-HTT loss in 
adolescent rats (35%) was, also, less extensive when compared to adult rats (49%) after 
MDMA exposure (Klomp et al 2012). In another study, Sprague-Dawley rats were injected 
with MDMA (20 mg/kg, s.c., twice daily, in four consecutive days) starting on embryonic 
day 15, or PND 10, 15, 20, 25, or 30 and were sacrificed on PND 40. Other group was 
also injected, with the same dose regimen, on PND 90, being sacrificed ten days after the 
drug treatment (Kelly et al 2002). The researchers observed no differences in the 5-HTT 
sites, on PND 40, in the brain of rats treated with MDMA at the development stages from 
E15 to PND 20, when compared to controls. However when MDMA treatment started on 
PND 25 or later, it resulted in significant reductions in the density of [3H]-paroxetine 
binding sites, with decreases of 46% at PND 25, and 63% at PND 30 compared to control, 
being the referred reductions not as intense as in animals treated at PND 90 (density of 
[3H]-paroxetine binding sites decreased by 90%) (Kelly et al 2002). These studies confirm 
that young animals are, apparently, less susceptible to MDMA than adults.  
In summary, the results in experiment two show that MDMA binge administration 
leads to hyperthermia in adolescent and old rats, with a higher magnitude in aged 
animals. One week after the MDMA administration, aged animals presented significant 
decreases in the cerebellum ATP content, indicating a higher susceptibility of this group to 
the neurotoxic effects of MDMA. Altogether, these findings confirm that aged animals are 
more susceptible to MDMA toxic actions than adolescents. 
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5.3. Conclusions 
 
In conclusion, the moderate binge dosage regimen of MDMA used, which was non-
neurotoxic to the serotonergic system and equivalent to the ones used by adolescent 
humans, did not promote any significant changes in oxidative stress related parameters in 
the brain areas of adolescent rats. Moreover, the same dose regimen acutely promoted a 
decrease in the ATP cortex content. Though frequently not evaluated in most studies, in 
the cerebellum, MDMA promoted neurotoxic effects in aged rats. Unfortunately, studies 
are mainly focused in the neurotoxicity of MDMA and neglect the toxicity promoted by this 
drug to the peripheral organs. The MDMA binge scheme used in this study promoted 
morphological tissue alterations to the peripheral organs of adolescent animals and 
increases in protein-bound quinone formation in the liver. More studies are needed to 
evaluate the impact of moderate MDMA doses in the brain and peripheral organs of 
adolescent animals and explore the different effects of MDMA to animals in dissimilar age 
stages. 
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